Page last updated: 2024-12-05

famotidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Famotidine is a potent H2 receptor antagonist that is used to treat various conditions associated with excess stomach acid, such as peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. Its synthesis involves a multi-step process starting from a commercially available thiazole derivative. Famotidine's mechanism of action involves blocking the histamine H2 receptors in the stomach, which are responsible for stimulating acid production. This leads to a reduction in gastric acid secretion. Famotidine is widely studied due to its efficacy in treating various acid-related disorders, its relatively low incidence of side effects, and its potential therapeutic applications in other areas, such as the treatment of certain types of cancer. Its effectiveness in reducing acid secretion makes it a valuable tool in the management of conditions characterized by excess stomach acid.'

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3325
MeSH IDM0024121
PubMed CID5702160
CHEBI ID4975
SCHEMBL ID974
SCHEMBL ID972
SCHEMBL ID23804905
MeSH IDM0024121

Synonyms (336)

Synonym
HMS3393A07
DIVK1C_000545
KBIO1_000545
n-sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
mk-208
n'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]propanimidamide
3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)propanimidamide
gastridin
famotidinum
3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-n(sup 2)-sulfamoylpropionamidine
quamatel
(1-amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
famotidina
SPECTRUM_001242
76824-35-6
famodine
ulfinol
hacip
gastrofam
vagostal
nevofam
apo-famotidine
gastridan
midefam
ulfagel
famopsin
invigan
rubacina
ulceprax
famowal
neocidine
cuantin
cepal
mensoma
nulcerin
tipodex
famotep
ulcofam
cronol
purifam
famotin
gastro
famodin
quamtel
topcid
renapepsa
famodar
confobos
bestidine
brolin
gastrion
pepcidin
peptidin
peptan
pepfamin
gastrodomina
famotal
tamin
nulceran
gastrosidin
famogard
famonit
huberdina
blocacid
apogastine
mylanta ar
ingastri
rogasti
ulfamid
ulgarine
restadin
novo-famotidine
antodine
panalba
famocid
notidin
logos
ulcatif
ulfam
mosul
famos
famovane
famotidine
pepcid
DB00927
KBIO2_006858
KBIO2_004290
KBIOSS_001722
KBIO3_002354
KBIO2_001722
KBIOGR_000676
SPBIO_002027
PRESTWICK0_000104
NINDS_000545
SPBIO_001251
PRESTWICK1_000104
SPECTRUM4_000408
SPECTRUM2_001036
SPECTRUM3_001427
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-n'-sulfamoylpropanimidamide
NCGC00018276-03
LP00497
AB03031
gtpl7074
HMS3372J17
n-sulfamoyl-3-[(2-guanidinothiazol-4-yl)methylthio]propionamidine
HMS3604N21
3-{[(2-carbamimidamido-1,3-thiazol-4-yl)methyl]sulfanyl}-n-sulfamoylpropanimidamide
AKOS026750161
HMS3655J17
pepcidin pepcidine
propanimidamide, 3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-n-(aminosulfonyl)-
(z)-3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-n'-sulfamoylpropanimidamide
SW197397-2
3-[[[2-[(diaminomethylene) amino]-4-thiazolyl]methyl]thio]-n2-sulfamoyl propionamidine
BCP22999
Q411159
3-((2-(diaminomethyleneamino)thiazol-4-yl)methylthio)-n-sulfamoylpropanimidamide
famotidine,(s)
D83176
famotidine 100 microg/ml in acetonitrile
SY058013
BIDD:GT0759
pepdine
pepcidine
CHEBI:4975 ,
gaster
ym-11170
famodil
pepdul
pepcid ac
pepcid rpd
pepcid ac gelcaps
ym-1170
PRESTWICK2_000104
(1z)-n'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide
PRESTWICK3_000104
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-n''-sulfamoylpropanimidamide
cid_5702160
bdbm22891
EU-0100497
PRESTWICK_212
NCGC00015446-01
cas-76824-35-6
NCGC00015446-02
lopac-f-6889
propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-n-(aminosulfonyl)
3-[(2-guanidinothiazol-4-yl)methylsulfanyl]-n-sulfamoyl-propanamidine
PDSP1_000398
LOPAC0_000497
BPBIO1_000098
BSPBIO_000088
pepcidac
lecedil
ganor
l 643341
gastropen
motiax
amfamox
famoxal
muclox
fluxid
famosan
propanimidamide, n'-(aminosulfonyl)-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-
MLS001423994
MLS000758205
pepcid (tn)
D00318
fluxid (tn)
famotidine (jp17/usp/inn)
PDSP2_000396
NCGC00093899-03
MLS000028583
smr000058961
NCGC00093899-01
NCGC00018276-02
NCGC00093899-02
NCGC00018276-01
NCGC00015446-03
L013386
HMS2051A07
F 6889 ,
AC-11713
n'-(aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
HMS2089I12
F0530 ,
3-(2-guanidinothiazol-4-ylmethylthio)-n1-sulfamoylpropionamide
NCGC00015446-06
nsc-757810
fadul
L003830
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-n'-sulfamoylpro
xufqphaneapemj-uhfffaoysa-
HMS1568E10
NCGC00015446-05
3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-n-(aminosulfonyl)propanimidamide
A838850
AKOS005460541
NCGC00188952-01
HMS3261D15
HMS2095E10
5qzo15j2z8 ,
tox21_301827
NCGC00255348-01
dtxsid5023039 ,
dtxcid803039
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-n-sulfamoylpropanimidamide
STK527689
(1z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-n'-sulfamoylpropanimidamide
tox21_110153
HMS2231I22
AKOS015994617
CCG-100767
NCGC00015446-04
famotidine [usan]
famotidine [usp monograph]
famotidine [jan]
famotidine [who-dd]
[1-amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propylidene]sulfamide
famotidine [mart.]
famotidine [inn]
famotidine component of pepcid complete
3-((((2-(diaminomethylene)amino)-4-thiazolyl)methyl)thio)-n-sulfamoylpropionamidine
famotidine [ep monograph]
famotidine [orange book]
famotidine [mi]
famotidine [vandf]
pepcid complete component famotidine
famotidine [hsdb]
famotidine [usp impurity]
famotidine [usp-rs]
S2078
CCG-220104
CCG-221801
HY-B0377
NC00017
SCHEMBL974
SCHEMBL972
NCGC00021202-03
tox21_110153_1
HS-0054 ,
tox21_500497
NCGC00261182-01
3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-n'-sulfamoylpropanimidamide
3-[({2-[(diaminomethylene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-n'-sulfamoylpropanimidamide
AC-31723
AB00383032_11
3-(((2-guanidinothiazol-4-yl)methyl)thio)-n-sulfamoylpropanimidamide
famotidine, united states pharmacopeia (usp) reference standard
famotidine, european pharmacopoeia (ep) reference standard
SR-05000001440-2
SR-05000001440-1
sr-05000001440
bdbm50103514
famotidine, pharmaceutical secondary standard; certified reference material
famotidine for system suitability, european pharmacopoeia (ep) reference standard
sr-01000075883
SR-01000075883-1
SBI-0050481.P003
HMS3712E10
famotidine, british pharmacopoeia (bp) reference standard
3-[2-(diaminomethyleneamino] thiazol-4-ylmethylthio]-n-sulphamoyl propionamidine
3-(2-(diaminomethyleneamino)-1,3-thiazol-4-yl)methylthio)-n'- sulfamoylpropionamidine
Z1521553705
famotidine (pepcid)
fo9 ,
EN300-119506
SDCCGSBI-0050481.P004
NCGC00015446-08
HMS3884J03
A899959
SCHEMBL23804905
pepcid acmaximum strength
acid controller
dg health heartburn prevention
caring mill famotidine
up and up famotidine
n-aminosulfonyl-3-((2-(diaminomethyleneamino)-1,3-thiazol-4-yl)methylsulfanyl)propanimidamide
good neighbor pharmacy acid reducer
signature care acid controllermaximum strength
famotidine tablet, film-coated
zantac 360 1 per blister 6 blisters
maximum strength
calmicid acacid reducer
famotidine 20 mg
famotidine (mart.)
acid controlleroriginal strength
basic care famotidine
topcare acid reducer
kirkland signature acid controller
acid controllermaximum strength
maximum strength acid controller
heartburn relieforiginal strength
good neighbor pharmacy acid reducermaximum strength
sunmark acid reducermaximum strength
sound body acid reducer
n'-(aminosulfonyl)-3-(((2-((diaminomethylidene)amino)-1,3-thiazol-4-yl)methyl)sulfanyl)propanimidamide
zantac 360 cool mint
signature care acid controller
rugby famotidine
acid reduceroriginal strength
equaline heartburn prevention
major heartburn reliefmaximum strength
premier value famotidine
betr acid reducer
dg health heartburn preventionoriginal strength
heartburn preventionoriginal strength
famotidine 10 mg
betr remedies acid reducer
famotidinum (latin)
sunmark acid reducer
basic care heartburn prevention
famotidineoriginal strength
foster and thrive acid reducer
famotidine (ep monograph)
members mark acid pep
famotidine (usp-rs)
good sense acid reducer
careone acid relief
acid relief
equate famotidine
maximum strength acid reducer
propanimidamide, n'-(aminosulfonyl)-3-
famotidine-acid controller
berkley and jensen famotidine
original strength heartburn prevention
zantac 360 2 per blister 6 blisters
zantac 360
dg health acid reducer
famotidine (usan:usp:inn:ban:jan)
famotidine (usp monograph)
pepcid acoriginal strength
acid reducermaximum strength
a02ba03
famotidine (usp impurity)
health mart famotidine

Research Excerpts

Overview

Famotidine is a competitive histamine H2-receptor antagonist most commonly used for gastric acid suppression. Thought to have potential efficacy in treating patients with Coronavirus disease 2019 (COVID-19)

ExcerptReferenceRelevance
"Famotidine is a competitive histamine H2-receptor antagonist most commonly used for gastric acid suppression but thought to have potential efficacy in treating patients with Coronavirus disease 2019 (COVID-19). "( Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis.
Chen, A; Chiu, L; Chiu, N; Chow, R; Hur, C; Lebwohl, B; Lo, CH; Prsic, EH; Shen, M; Shin, HJ, 2021
)
2.47
"Famotidine (FMT) is a competitive histamine-2 (H2) receptor antagonist that inhibits gastric acid secretion for the treatment of Gastroesophageal reflux disease. "( Promoting Activity of Terpenes on Skin Permeation of Famotidine.
Fukuzawa, K; Furuishi, T; Obata, Y; Ofuchi, Y; Saito, H; Setoyama, H; Wu, Y; Xu, Q; Yonemochi, E, 2023
)
2.6
"Famotidine is a histamine-2 (H2) receptor antagonist which blocks the H2 receptors in the parietal cells, decreasing gastric acid secretion."( Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Chenchula, S; Ray, A; Sadasivam, B, 2021
)
2.79
"Famotidine is a histamine-2 (H2) receptor antagonist which blocks the H2 receptors in the parietal cells, decreasing gastric acid secretion."( Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Chenchula, S; Ray, A; Sadasivam, B, 2021
)
2.79
"Famotidine is an acid suppressant commonly administered to dogs. "( Repeated Famotidine Administration Results in a Diminished Effect on Intragastric pH in Dogs.
Graham, A; Hecht, S; Newkirk, K; Odunayo, A; Price, J; Steiner, JM; Tolbert, MK, 2017
)
2.31
"Famotidine (FAM) is an H2-antagonist for which the propensity for idiosyncratic reactions is far less than RAN."( Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats.
Cockerell, GL; Cosma, GN; Ganey, PE; Luyendyk, JP; Maddox, JF; Roth, RA, 2003
)
1.04
"Famotidine is an H2-histamine receptor antagonist that reduces gastric acid and pepsin secretion to an extent at least as great as gastric vagotomy."( Blockade of digestion by famotidine pretreatment does not interfere with the opioid-enhancing effect of ingested amniotic fluid.
Abbott, P; Kristal, MB; Robinson, TM, 1995
)
1.32
"Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier."( Famotidine as an adjunct treatment of resistant schizophrenia.
Merskey, H; Oyewumi, LK; Plumb, C; Vollick, D, 1994
)
2.45
"Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost. "( Famotidine-associated delirium. A series of six cases.
Alberts, VA; Catalano, G; Catalano, MC,
)
3.02
"Famotidine is a specific, long-acting histamine2-receptor antagonist. "( The tolerability and safety profile of famotidine.
Howden, CW; Tytgat, GN,
)
1.84
"Famotidine is found to be a very effective ligand for Ni2+ ions also."( Famotidine, the new antiulcero-genic agent, a potent ligand for metal ions.
Anouar, A; Decock, P; Ganadu, ML; Kowalik-Jankowska, T; Kozłowski, H; Spychala, J; Swiatek, J, 1992
)
2.45
"Famotidine is a very useful H2-receptor antagonist for the treatment of most patients with GERD."( Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp, IC, 1992
)
2.45
"Famotidine is a weaker inhibitor of the organic cation system compared with cimetidine and ranitidine."( Effect of H2 antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney.
Muirhead, MR; Somogyi, AA,
)
0.85
"Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. "( Clinical pharmacokinetics of famotidine.
Echizen, H; Ishizaki, T, 1991
)
2.02
"Famotidine is a highly selective histamine H2-receptor antagonist. "( Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Goa, KL; Grant, SM; Langtry, HD, 1989
)
3.16
"1) famotidine appears to be an effective and safe therapy for duodenal ulcer treatment; 2) it seems to act not only by inhibiting gastric acid secretion but also influencing some parameters related to the gastric mucosal barrier."( [Famotidine in the short and long term treatment of duodenal ulcer: clinical and physiopathologic study].
Dal Santo, L; Di Mario, F; Gottardello, L; Grassi, SA; Naccarato, R; Pasqualetti, P; Tessaro, P; Vianello, F; Vio, A, 1989
)
1.81
"Famotidine proved to be a potent inhibitor of both the parietal component of gastric acid and pepsin output."( Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.
Chremos, AN; Gamal, MA; Graham, DY; Smith, JL, 1985
)
2.43
"Famotidine is a new histamine H2-receptor antagonist. "( Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Campoli-Richards, DM; Clissold, SP, 1986
)
3.16
"Famotidine is a new potent competitive inhibitor of H2 receptors."( Pharmacodynamics of famotidine in humans.
Chremos, AN, 1986
)
1.32
"Famotidine is a potent histamine (H2)-receptor antagonist that binds to the H2 receptor in a competitive reversible manner as shown by in vivo, in vitro, and clinical studies. "( Famotidine: an appraisal of its mode of action and safety.
Berlin, RG; Clineschmidt, BV; Majka, JA, 1986
)
3.16
"Famotidine appears to be an effective and safe once-a-day therapy for the treatment of acute duodenal ulcer disease."( A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease.
Berman, R; Gitlin, N; Mantell, G; McCullough, AJ; Smith, JL, 1987
)
1.21
"Famotidine is a new histamine H2-receptor antagonist which has been demonstrated to be more potent than cimetidine and ranitidine in inhibiting gastric acid secretion. "( Urinary excretion kinetics of famotidine in rats.
Duggan, DE; Lin, JH; Los, LE; Ulm, EH,
)
1.86
"Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine. "( Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
, 1987
)
3.16
"Famotidine is an even more potent H2 receptor antagonist, and initial clinical studies are promising."( Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
Mahachai, V; Thomson, AB, 1987
)
0.99
"Famotidine is a competitive histamine H2-receptor antagonist. "( Clinical pharmacology of famotidine: a summary.
Chremos, AN, 1987
)
2.02
"Famotidine (F) is an effective new H2-receptor antagonist. "( Pharmacokinetics of famotidine in man.
Klotz, U; Kroemer, H, 1987
)
2.04
"Famotidine appears to be an effective treatment for acute duodenal ulcer."( Famotidine versus cimetidine in the treatment of acute duodenal ulcer. Double-blind, randomized clinical trial comparing nocturnal administration of 40 mg famotidine to 800 mg cimetidine.
Fölsch, UR; Hartmann, H, 1988
)
2.44

Effects

Famotidine (FMT) has low oral bioavailability of 40-45% and short half-life between 2.5 to 4 h. Famotidine HCl has low bioavailability (40-45%) due to its narrow absorption window and low solubility in intestinal pH.

ExcerptReferenceRelevance
"Famotidine has been considered to be a potential treatment for COVID-19 but the current data is conflicting. "( The association between famotidine and in-hospital mortality of patients with COVID-19.
Egorova, NN; Kuno, T; So, M; Takahashi, M, 2022
)
2.47
"Famotidine has since been shown to improve patient outcomes and reduce symptom severity in patients acutely ill with COVID-19."( Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.
Alnouri, G; Balouch, B; Sataloff, RT; Vontela, S; Yeakel, H, 2023
)
2.07
"Famotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. "( Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.
Ayaz Ahmed, M; Bhan, C; Chen, Y; Guo, Z; Hu, L; Liang, M; Sun, C; Wu, Y; Yan, Y; Yang, H; Zhou, Q; Zuo, Y, 2021
)
2.58
"Famotidine has the potential to answer the ongoing global challenge owing to its selective action on viral replication. "( Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Chenchula, S; Ray, A; Sadasivam, B, 2021
)
3.51
"Famotidine has the potential to answer the ongoing global challenge owing to its selective action on viral replication. "( Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Chenchula, S; Ray, A; Sadasivam, B, 2021
)
3.51
"Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). "( Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.
Berlin, JA; Fortin, SP; Ryan, P; Shoaibi, A; Weinstein, R, 2021
)
2.36
"Famotidine (FMT) has low oral bioavailability of 40-45% and short half-life between 2.5 to 4 h."( Optimized Mucoadhesive Coated Niosomes as a Sustained Oral Delivery System of Famotidine.
Abdul Rasool, BK; Khalifa, AM, 2017
)
1.4
"Famotidine HCl has low bioavailability (40-45%) due to its narrow absorption window and low solubility in intestinal pH. "( Design and development of novel lipid based gastroretentive delivery system: response surface analysis, in-vivo imaging and pharmacokinetic study.
Ahmed Abdelbary, A; Elsayed, I; Hassen Elshafeey, A, 2015
)
1.86
"Famotidine has been used for the treatment of peptic ulcers and Zollinger Ellison syndrome and is also useful in reflux and erosive oesophagitis. "( Famotidine in the management of gastro-oesophageal reflux.
Dubois, C; Lule, GN; Ogutu, EO; Okoth, FA; Pilczer, S, 1994
)
3.17
"Famotidine also has such effects."( Interaction of the new histamine H2-receptor antagonist pibutidine hydrochloride with canine cloned H2-receptor expressed cells.
Higuchi, S; Isobe, Y; Kaku, S; Kiuchi, Y; Muramatsu, M; Tanaka, M, 1999
)
1.02
"Famotidine has been already demonstrated to be a competitive H2-receptor antagonist in the stomachs of dogs and cats. "( Selective and competitive histamine H2-receptor blocking effect of famotidine on the blood pressure response in dogs and the acid secretory response in rats.
Fujihara, A; Kamato, T; Miyata, K; Takeda, M, 1990
)
1.96
"Famotidine has no action on membrane components activating the adenylate cyclase system, including the Gs subunit of the enzyme stimulated by forskolin and cell surface receptors sensitive to isoproterenol (beta 2-type), PGE2 and VIP."( Pharmacological control of the human gastric histamine H2 receptor by famotidine: comparison with H1, H2 and H3 receptor agonists and antagonists.
Emami, S; Fagot, D; Gespach, C, 1989
)
1.23
"Famotidine has shown no evidence of carcinogenicity, mutagenicity, or teratogenicity in extensive and adequately designed safety assessment studies."( Famotidine: an appraisal of its mode of action and safety.
Berlin, RG; Clineschmidt, BV; Majka, JA, 1986
)
2.44
"Famotidine has no known drug interactions and there are no identified mechanisms by which it might be expected to produce them."( The place of famotidine in anti-ulcer therapy.
Mann, SG, 1987
)
1.36

Actions

Famotidine increased the lower esophagus sphincter pressure. It had no effect on the esophageal body motility parameters. Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes.

ExcerptReferenceRelevance
"Famotidine may enhance the LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes."( Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Quan, FM; Quan, WD, 2014
)
1.37
"Famotidine resulted in lower AUC while food had no effect."( Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
Bendell, JC; Clary, DO; Dickson, MA; Edelman, G; Gordon, MS; Johnston, SH; Kudchadkar, RR; LoRusso, PM; Schwartz, GK, 2015
)
1.14
"Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes."( High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
King, LA; Liles, DK; Picton, M; Quan, FM; Quan, WD; Tyre, C; Walker, PR, 2008
)
1.33
"As famotidine did not inhibit ghrelin-induced acid secretion in the study by Masuda et al, they concluded that histamine was not involved in the action of ghrelin on acid secretion."( Ghrelin and gastric acid secretion.
Kato, S; Kawashima, J; Yakabi, K, 2008
)
0.86
"Famotidine may increase LAK cytotoxicity against neoplastic cells by allowing for greater IL-2 uptake at the IL-2 receptor on lymphocytes."( Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Quan, FM; Quan, WD, 2009
)
1.32
"Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes."( Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Knupp, C; Quan, F; Quan, W; Walker, P, 2010
)
1.36
"Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes."( Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
Johnson, E; Perez, M; Quan, FM; Quan, WD, 2012
)
1.36
"Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes."( High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004
)
1.29
"Famotidine may enhance LAK cytolytic ability."( High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
Khan, N; Quan, F; Quan, W; Ramirez, M; Taylor, C; Vinogradov, M, 2005
)
1.29
"Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes."( Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
King, LA; Quan, FM; Quan, WD; Walker, PR, 2008
)
1.3
"Famotidine can cause clinical hepatitis, and drug-induced hepatitis can occur after the administration of two different H2-receptor blockers."( Hepatitis following treatments with famotidine and then cimetidine.
Davis, RL; Egli, D; Hashimoto, F, 1994
)
2.01
"Famotidine increased the lower esophagus sphincter pressure from the initial 2.31 +/- 1.19 kPa to 3.51 +/- 1.61 kPa (p < 0.05) and had no effect on the esophageal body motility parameters."( [The effect of cimetidine and famotidine on esophageal motility].
Paradowski, L; Salomon, A; Szelag, A, 1996
)
1.3
"Famotidine may produce less neurological side effects in patients with liver disease than the histamine H2-receptor antagonists used currently."( Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan, MY; Stambuk, D, 1986
)
2.44

Treatment

Famotidine pretreatment lowered GDC-0941 exposure by 5-fold, and decreased dasatinib measurable concentrations 30-fold. Famotidine treatment did not lead to abnormal respiration, heart rate and blood pressure.

ExcerptReferenceRelevance
"Famotidine treatment was not associated with a lower risk of in-hospital mortality of COVID-19 patients."( The association between famotidine and in-hospital mortality of patients with COVID-19.
Egorova, NN; Kuno, T; So, M; Takahashi, M, 2022
)
1.75
"Famotidine pretreatment lowered GDC-0941 exposure by 5-fold, and decreased dasatinib measurable concentrations 30-fold, compared to the pentagastrin-treated dogs."( Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Dalziel, G; Dean, B; Pang, J; Salphati, L; Ware, JA, 2013
)
1.11
"Famotidine treatment did not lead to abnormal respiration, heart rate and blood pressure."( [Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
Wu, YY, 2008
)
1.37
"Famotidine treatment suppressed the mRNA expressions of Col10a1 and osteocalcin, ossification markers, in a tendon-derived cell line TT-D6, as well as a preosteoblastic one MC3T3-E1."( Famotidine suppresses osteogenic differentiation of tendon cells in vitro and pathological calcification of tendon in vivo.
Chung, UI; Hojo, H; Koshima, I; Ohba, S; Yamamoto, K, 2012
)
2.54
"Ten famotidine-treated cases (67%) showed significant lymphocytic infiltration in the center compared to 4 controls (27%) (p = 0.03)."( Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study.
Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002
)
1.31
"Famotidine treatment including metronidazole-amoxicillin as second-line therapy provided a high eradication rate similar to lansoprazole therapy. "( Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K, 2006
)
2.04
"Famotidine treatment had virtually no effect on any of theophylline's pharmacokinetic parameters."( Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.
Bachmann, K; Jauregui, L; King, JD; Miller, K; Reese, JH; Schwartz, J; Scott, M; Stepanavage, M; Sullivan, TJ; Yeh, KC, 1995
)
1.26
"Famotidine treatment in the evening was more effective than in the morning (634 vs 463 min or 5.22 vs 3.10)."( Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry.
Garamszegi, M; Hunyady, B; Juricskay, I; Mózsik, G; Nagy, L; Vincze, A, 1996
)
1.26
"Famotidine treatment alone (20 mg/kg."( Interaction of nicotine and a H2-receptor antagonist, famotidine, on gastrin and chromogranin A expression.
Gomez, G; Greeley, GH; Udupi, V, 1997
)
1.27
"Famotidine treatment had no significant effect on grepafloxacin pharmacokinetics."( Effect of food and gastric pH on the bioavailability of grepafloxacin.
Bramer, SL; Efthymiopoulos, C; Maroli, A, 1997
)
1.02
"The famotidine treatment was significantly more effective at rapidly reducing the incidence of ulcer-related symptoms."( Famotidine once-a-day in the therapy of acute, benign gastric ulcer: a worldwide experience.
Dammann, HG; Müller, P; Simon, B, 1987
)
2.2
"Pretreatment with famotidine [40 mg orally] 1 h prior to test compound administration was determined to be adequate for simulating human gastric pH when acid-reducing agents are coadministered."( Development of a canine model to enable the preclinical assessment of pH-dependent absorption of test compounds.
Derbin, G; Fancher, RM; Marathe, P; Rockar, R; Sleczka, B; Zhang, H, 2011
)
0.69
"Treatment with famotidine significantly reduced the severity score compared with control (P = .0004). "( Efficacy of famotidine for the prevention of exercise-induced gastritis in racing Alaskan sled dogs.
Davis, MS; McKenzie, EC; Payton, ME; Royer, CM; Willard, MD; Williamson, KK,
)
0.86
"Pretreatment with famotidine or omeprazole reduced lesion index, and the protective effects were equivalent to those of 1.0 mg/kg of FK506, although FK506 did not affect gastric secretion during water-immersion stress."( Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats.
Goto, H; Hamajima, E; Hoshino, H; Ozawa, T; Sugiyama, S; Tsukamoto, Y, 1994
)
0.61
"Pretreatment with famotidine resulted in a slight increase of macroscopically visible gastric lesions in response to HCl."( Famotidine prevents deep histologic lesions induced by 0.6N HCl in rat gastric mucosa: role of parietal cells.
Grandi, D; Morini, G, 2000
)
2.07
"The treatment with famotidine (groups II and III) did not inhibit hepatocyte mitosis but, on the contrary, raised the index on day 3 after hepatectomy when compared with the controls (group I)."( Famotidine does not inhibit liver regeneration.
Kanashima, R; Kobayashi, M, 1989
)
2.04
"Pretreatment with famotidine prevented decreases in levels of PGs, which are known to have cytoprotective effect, and also maintained PLase activity."( Effect of the H2-blocker famotidine on gastric mucosal prostaglandin levels in water immersion stress in rats.
Goto, H; Nakazawa, S; Ozawa, T; Sugiyama, S; Takano, K, 1988
)
0.9

Toxicity

Famotidine was used to treat dogs with cancer treated with piroxicam. Possible adverse effects of famotidine treatmentdouble ended arrowrelated were observed.

ExcerptReferenceRelevance
" Despite that all those who failed to show ulcer healing at 4-week were smokers, logistic regression analysis could not identify smoking or any other risk factors as adverse predictors of ulcer healing."( A single nocturnal dose of famotidine for the treatment of duodenal ulcer: evaluation of efficacy and safety.
al-Freihi, HM; al-Ghassab, G; al-Gindan, YM; al-Hamdan, A; al-Qurain, A; Ibrahim, EM; Nabi, HI,
)
0.43
" Data on patient demographics, drug administration time, adverse effects, cardiovascular variables, and costs (including drug acquisition, supply, and nursing personnel costs) were collected prospectively."( Safety and cost of rapid i.v. injection of famotidine in critically ill patients.
Fish, DN, 1995
)
0.55
" In the present article, the adverse effects of PPIs are reviewed, with special emphasis on those related to their continued administration and on the special circumstances of patients, as in the case of the elderly, those with liver failure, pregnant and breastfeeding mothers and children."( [Safety of proton pump inhibitors].
Esplugues, JV; Martí-Cabrera, M; Ponce, J, 2006
)
0.33
" Possible adverse effects of famotidine treatmentdouble ended arrowrelated were observed."( [Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
Wu, YY, 2008
)
0.94
" An augmented side effect of the other drugs concurrently used due to famotidine treatment was not noted."( [Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
Wu, YY, 2008
)
0.89
"Famotidide is effective and safe for the treatment of stress ulcers in neonates."( [Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
Wu, YY, 2008
)
0.65
"To investigate spontaneous reports of TdP present in the public version of the FDA Adverse Event Reporting System (AERS) in the light of what is already known on their TdP-liability."( Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009
)
0.35
" Cases were represented by TdP reports, whereas non-cases were all reports of adverse drug reactions other than TdP."( Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009
)
0.35
"Large spontaneous reporting databases represent an important source for signal detection of rare adverse drug reactions (ADR), such as TdP."( Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009
)
0.35
"Osteoarthritis patients from previously completed randomized, double-blind, comparison registration trials (REDUCE-1 and 2) which included a broad pain patient population, were pooled and analyzed for (1) the risk of endoscopically identified UGI ulcers over 24 weeks and (2) comparative pre-specified treatment emergent adverse events (TEAEs)."( Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014
)
0.62
" Adverse events of special interest were generally similar between the 2 groups, with the exception of dyspepsia."( Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014
)
0.62
" Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)."( One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015
)
0.64
"Most patients (65%) finished the trial, with 76% contributing data at 6 months, and 21% withdrew due to adverse effects."( One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015
)
0.64
" Safety was assessed by monitoring the incidence, causality, and severity of adverse events (AEs)."( One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension.
Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015
)
0.71
" Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects."( Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.
Allakonda, L; Kondru, SK; Konduri, P; Potnuri, AG, 2018
)
0.48
"To assess the impact of prophylactic omeprazole and famotidine on the incidence and severity of gastrointestinal (GI) adverse events (AEs) in dogs with cancer treated with single agent piroxicam."( A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine.
Fulkerson, CM; Moore, GE; Shaevitz, MH, 2021
)
1.05
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

Famotidine significantly increased the terminal elimination half-life of ciprofloxacin. Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AU)

ExcerptReferenceRelevance
" Plasma data were subjected to non compartmental pharmacokinetic analysis."( Pharmacokinetics of famotidine in patients with cirrhosis and ascites.
Baldit, C; Bannwarth, B; Begaud, B; Couzigou, P; Demotes-Mainard, F; Elouaer-Blanc, L; Vinçon, G, 1992
)
0.61
" The plasma terminal elimination half-life of famotidine was significantly prolonged and famotidine total body clearance was significantly reduced in patients with decompensated cirrhosis, whose creatinine clearance was 57."( Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi, K, 1991
)
0.86
"The pharmacokinetic and pharmacodynamic properties of the H2-receptor antagonist famotidine have been well described in adult subjects."( Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.
Chmelarsch, D; Klotz, U; Kraus, G; Krishna, DR; Schmid, M, 1990
)
1.95
" Elimination half-life in the elderly patients with renal insufficiency was significantly prolonged compared to the elderly patients with normal renal function and the young volunteers."( Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
Fujiyama, S; Imai, Y; Inotsume, N; Matsui, H; Nakano, M; Nishimura, M; Sagara, K; Sato, T, 1989
)
0.6
" Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38."( Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats.
Ferguson, RK; Mojaverian, P; Rocci, ML; Saccar, CL; Vlasses, PH,
)
0.83
" Knowledge of its pharmacokinetic properties and metabolism is scanty."( Pharmacokinetics of famotidine in man.
Klotz, U; Kroemer, H, 1987
)
0.6
" A 7 to 10 fold prolongation of famotidine's elimination half-life (27."( Pharmacokinetics and dynamics of famotidine in patients with renal failure.
Gladziwa, U; Glöckner, WM; Klotz, U; Krishna, DR; Mann, H; Schmitt, H, 1988
)
0.84
"A four-way crossover pilot study was conducted to compare the pharmacodynamic response of intermittent famotidine (20 mg every 12 hr) to continuous infusions of cimetidine (1200 mg/24 hr), ranitidine (150 mg/24 hr), and famotidine (40 mg/24 hr) in six normal male volunteers."( Pharmacodynamics of bolus famotidine versus infused cimetidine, ranitidine, and famotidine.
Amsden, GW; D'Andrea, DT; Goss, TF; Harrison, NJ; Schentag, JJ, 1994
)
0.8
" Pharmacokinetic parameters were calculated assuming a one-compartment model."( Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
Aoki, S; Ashida, K; Manago, M; Mino, M; Nagita, A; Suzuki, K, 1994
)
0.55
"The possibility of a pharmacokinetic interaction between H2-receptor antagonists and alcohol consumed at lunchtime, was investigated in 24 healthy non-alcoholic male subjects, each receiving ranitidine 150 mg four times daily, cimetidine 400 mg four times daily, famotidine 20 mg four times daily and placebo in an open, four-way cross-over study."( Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime.
Braithwaite, R; Gibson, GJ; Hale, KA; Kendall, MJ; Langman, MJ; Spannuth, F; Walt, RP, 1994
)
0.47
" Famotidine's plasma half-life (4."( Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison.
Bisson, C; LeBel, M; Michaud, JT; St-Laurent, M,
)
1.29
"The pharmacokinetics, pharmacodynamic effect and clinical efficacy of famotidine were studied in 10 patients with reflux oesophagitis Grades I and II."( Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
Dakshinamurty, KV; Dreuw, B; el Desoky, E; Gladziwa, U; Klotz, U; Wagner, S, 1993
)
0.79
" Blood samples were collected just before each dose of cyclosporine and for up to 36 hours afterward for pharmacokinetic analysis."( Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men.
Collier, DS; McGuire, TR; Rossi, SJ; Schaaf, LJ; Shaefer, MS; Stratta, RJ, 1995
)
0.53
" Cyclosporine pharmacokinetic parameters during each of the 3 treatment periods were compared."( Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men.
Collier, DS; McGuire, TR; Rossi, SJ; Schaaf, LJ; Shaefer, MS; Stratta, RJ, 1995
)
0.53
" Pharmacokinetic parameters were determined from curve fitting of serum concentration data."( Pharmacokinetics and pharmacodynamics of famotidine in children.
Heulitt, MJ; James, LP; Kearns, GL; Letzig, L; Marshall, JD; Wells, TG, 1996
)
0.56
" The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs."( Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Berstad, A; Hatlebakk, JG, 1996
)
0.29
" A significant decrease in maximum concentration (Cmax) and increase in time to Cmax (tmax) was observed for vesnarinone during treatment with famotidine, whereas area under the concentration-time curve (AUC) was similar for both treatments."( Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone.
Bramer, SL; Cowart, DT; Kisicki, J; Koneru, B; Noorisa, M, 1998
)
0.77
"66 ng/mL, the elimination half-life (t1/2 beta) was 10."( Pharmacokinetics and pharmacodynamics of famotidine in infants.
Farrar, HC; James, LP; Kearns, GL; Marotti, T; Stowe, CD; Taylor, BJ, 1998
)
0.57
" The methods were utilized to support clinical pharmacokinetic studies in infants aged 0-12 months."( Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry.
Eisenhandler, R; Yeh, KC; Zhong, L, 2001
)
0.65
" Pharmacokinetic parameters were assessed using non-compartmental methodology."( Food effects on the absorption and pharmacokinetics of cocoa flavanols.
Ensunsa, JL; Holt, RR; Karim, M; Keen, CL; Kirkpatrick, NJ; Polagruto, JA; Schmitz, HH; Schrader, HR; Schramm, DD, 2003
)
0.32
"5 mg/kg intravenously were divided into two groups by age, and pharmacokinetic parameters in infants 0-3 months and >3 to 12 months of age were compared."( Pharmacokinetics of famotidine in infants.
Baier, J; Blumer, JL; Eisenhandler, R; James, LP; Kearns, GL; Marshall, JD; Murphy, MG; Panebianco, DL; Scheimann, AO; Wenning, LA; Yeh, KC; Zhong, L, 2005
)
0.65
" Pharmacokinetic parameters for the older infants (i."( Pharmacokinetics of famotidine in infants.
Baier, J; Blumer, JL; Eisenhandler, R; James, LP; Kearns, GL; Marshall, JD; Murphy, MG; Panebianco, DL; Scheimann, AO; Wenning, LA; Yeh, KC; Zhong, L, 2005
)
0.65
" The pharmacokinetic parameters (elimination half-life, area under the plasma concentration-time curve, peak plasma levels and the times to attain these plasma levels) of verapamil were evaluated in the rat."( Influence of famotidine on verapamil pharmacokinetics in rats.
Matar, KM,
)
0.5
" The aim of this study was to compare the pharmacokinetic and pharmacodynamic properties of lafutidine and famotidine following postprandial oral administration."( Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.
Hayato, S; Ikawa, K; Morikawa, N; Shimatani, T; Tazuma, S, 2007
)
0.76
" The aim of this study was to investigate the pharmacokinetic alteration of cationic drugs and the expression of tubular organic cation transporters, rOCT1, rOCT2, and rMATE1, in ischemia/reperfusion (I/R)-induced AKI rats."( Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury.
Hamada, A; Inui, K; Matsuzaki, T; Morisaki, T; Nonoguchi, H; Saito, H; Sato, D; Sugimoto, W; Terada, T; Tomita, K; Yokoo, K, 2008
)
0.35
"Significant pharmacokinetic interactions can result between acid-suppressing agents and some protease inhibitors (PIs) in the management of HIV infection."( Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L, 2011
)
0.64
"Eighteen patients treated with dasatinib and H2RA, PPI or no acid suppressant from whom were obtained a total of 34 pharmacokinetic profiles were enrolled in the study."( Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Miura, M; Niioka, T; Sawada, K; Takahashi, N, 2012
)
0.38
" No difference between drugs in clearance, volume of distribution and half-life (p > 0."( Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Kauffman, R; Lai, ML; Lehr, VT; Madani, S; Sarniak, A; Simpson, P; Tolia, V, 2014
)
0.67
"The objective of this study was to determine the impact of a pharmacy-managed pharmacokinetic dosing program on appropriate dosing of famotidine, enoxaparin, and ketorolac."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.62
"A large community teaching hospital implemented a pharmacy-managed pharmacokinetic dosing program for famotidine, enoxaparin, and ketorolac."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.63
"Implementation of a pharmacy-managed pharmacokinetic dosing program significantly improved appropriate dosing of famotidine, enoxaparin, and ketorolac."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.63
" A pharmacokinetic (PK) absorption model was employed to guide the formulation development and selection."( Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
Crison, J; Fung, NK; Good, DJ; Haddadin, R; Hartley, R; Hussain, M; Koo, O; Mathias, N; Nikfar, F; Timmins, P; Tirucherai, G, 2015
)
0.42
" A third objective was to describe the pharmacokinetic parameters of IV famotidine in cattle."( Pharmacokinetics and efficacy of intravenous famotidine in adult cattle.
Balcomb, CC; Chigerwe, M; Heller, MC; Knych, HK; Meyer, AM, 2018
)
0.97
"Although acid suppressants are needed to attenuate gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI), pharmacodynamic interaction between clopidogrel and proton pump inhibitor (PPI) can increase the risk of high platelet reactivity (HPR)."( Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial.
Ahn, JH; Bae, JS; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, KH; Koh, JS; Kwak, CH; Park, JR; Park, Y, 2020
)
0.85
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

High-dose famotidine and omeprazole, combined with clarithromycin and metronidazole, are equally effective for eradication of H. The renal drug-drug interaction betweenfamotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats.

ExcerptReferenceRelevance
"The most widely used H2-receptor antagonist, cimetidine, is known to interact with cytochrome P-450 drug-metabolizing enzymes and, therefore, interacts with other drugs which may be administered concurrently."( Comparative effects of H2-receptor antagonists on drug interaction in rats.
Cocchetto, DM; Duggan, DE; Lin, JH; Yeh, KC,
)
0.13
" The potential of famotidine, a new H2-receptor antagonist with a guanylthiazole ring structure, to interact with the cytochrome P450 system has been extensively evaluated."( Famotidine: a notable lack of drug interactions.
Humphries, TJ, 1987
)
2.05
" The aim of our study was to evaluate the effects of proton pump inhibitors alone or in combination with H2 receptor blockers on gastric acidity with 24-hour gastric pH monitoring."( The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Bektaş, M; Cetinkaya, H; Ozden, A; Soykan, I; Törüner, M, 2004
)
0.32
"The renal drug-drug interaction between famotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats."( Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
Chida, M; Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2006
)
0.6
"We investigated savolitinib pharmacokinetics (PK) when administered alone or in combination with rifampicin, itraconazole or famotidine, and investigated midazolam PK when administered with or without savolitinib in healthy males."( Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam.
Burke, W; Cantarini, M; Frewer, P; Goldwater, R; Han, D; Hara, I; Li, Y; Ren, S; Scarfe, G; Schalkwijk, S; Vishwanathan, K, 2022
)
1.14
"The renal drug-drug interaction between famotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats."( Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
Chida, M; Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2006
)
0.33

Bioavailability

The effect of a high potency antacid on the oral bioavailability of a single dose of famotidine (40 mg) was evaluated in normal volunteers. In vivo, therapeutic doses of cimetidine increased blood ethanol levels when ethanol was given orally, but not when it was given intravenously.

ExcerptReferenceRelevance
" In this study, the absorption and bioavailability of oral doses of each of three H2RAs, which are possible factors in these effects, were studied in healthy volunteers."( Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai, K, 1992
)
0.28
"To determine whether the H2-receptor antagonist, ranitidine, which is a potent inhibitor of gastric alcohol dehydrogenase activity in vitro, increases the bioavailability of orally administered ethanol (0."( Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists.
Baraona, E; DiPadova, C; Frezza, M; Gentry, RT; Lieber, CS; Roine, R, 1992
)
0.28
"Peak blood alcohol concentrations, areas under the blood alcohol curve, first-pass metabolism, and bioavailability of orally consumed ethanol."( Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists.
Baraona, E; DiPadova, C; Frezza, M; Gentry, RT; Lieber, CS; Roine, R, 1992
)
0.28
" First-pass metabolism of ethanol was decreased from 70 +/- 10 to 31 +/- 9 mg/kg of body weight, with a corresponding increase in ethanol bioavailability of 79."( Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists.
Baraona, E; DiPadova, C; Frezza, M; Gentry, RT; Lieber, CS; Roine, R, 1992
)
0.28
" After oral administration, peak plasma concentrations are attained within 2 to 4h; the oral bioavailability ranges from 40 to 50%, due mainly to incomplete absorption."( Clinical pharmacokinetics of famotidine.
Echizen, H; Ishizaki, T, 1991
)
0.57
"The pharmacokinetics and bioavailability of famotidine were investigated by HPLC method in 10 Chinese healthy volunteers."( Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers.
Gao, S; Gao, XH; Liu, GL; Wang, SX, 1991
)
0.81
" In vivo, therapeutic doses of cimetidine (but not of famotidine) increased blood ethanol levels when ethanol was given orally, but not when it was given intravenously, indicating a significant contribution of the gastric ADH to the bioavailability and thereby the potential toxicity of ethanol."( Human gastric alcohol dehydrogenase: its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol.
Baraona, E; Caballeria, J; Greenstein, R; Hernández-Muñoz, R; Lieber, CS; Uppal, R, 1990
)
0.53
" Variations in gastric pH have negligible effect on the bioavailability of mesalazine in vivo."( Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption.
Mulder, CJ; Rietbroek, R; Stolk, LM; Tytgat, GN; Verbeek, C; Wiltink, EH, 1990
)
0.51
"The effect of a high potency antacid on the oral bioavailability of a single dose of famotidine (40 mg) was evaluated in normal volunteers according to a randomized cross-over design."( Impaired bioavailability of famotidine given concurrently with a potent antacid.
Barzaghi, N; Crema, F; Gatti, G; Perucca, E, 1989
)
0.79
" In addition to the earlier onset of effect, intravenous famotidine is about twice as potent as oral, a result consistent with a systemic bioavailability of oral famotidine of about 43%."( Clinical pharmacology of famotidine: a summary.
Chremos, AN, 1987
)
0.82
"1 h and its absolute bioavailability ranged from 20 to 66%."( Pharmacokinetics of famotidine in man.
Klotz, U; Kroemer, H, 1987
)
0.6
"The effect of a high potency antacid and food on the bioavailability of famotidine was studied in 17 healthy volunteers in an open randomized three-way cross-over trial."( Effects of antacids and food on absorption of famotidine.
Chremos, AN; Kann, J; Kanovsky, SM; Lin, JH; Schwartz, S; Yeh, KC, 1987
)
0.76
"Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies."( Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
Antonello, J; Chremos, AN; Constanzer, ML; Hucker, HB; Kanovsky, SM; Lin, JH; Ryan, JR; Vlasses, P; Williams, RL; Yeh, KC,
)
0.65
" The bioavailability after oral administration was 49."( Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
Ando, K; Hachisu, T; Hattori, Y; Oda, Y; Yokoyama, T; Yoshida, T, 1988
)
0.56
" The mean oral bioavailability of famotidine was 50."( Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
Aoki, S; Ashida, K; Manago, M; Mino, M; Nagita, A; Suzuki, K, 1994
)
0.83
" Second, the effect of magnesium/aluminium hydroxide on the relative bioavailability of nizatidine, famotidine, cimetidine and ranitidine was evaluated in healthy volunteers."( Drug interactions of H2-receptor antagonists.
Bachmann, KA; Jauregui, L; Levine, L; Miller, K; Reese, J; Sullivan, TJ, 1994
)
0.5
"The bioavailability of dipyridamole, a poorly soluble weak base, was evaluated in 11 healthy, older subjects (> or = 65 years), 6 with a low fasting gastric pH (control) and 5 with a fasting gastric pH > 5 (achlorhydric), in a randomized, crossover design."( pH-related changes in the absorption of dipyridamole in the elderly.
Barnett, JL; Berardi, RR; Dressman, JB; O'Sullivan, TL; Russell, TL; Wagner, JG, 1994
)
0.29
"The influence of concomitant antacid administration on the relative bioavailability of the H2-receptor antagonists cimetidine, famotidine, nizatidine and ranitidine, was investigated in a panel of 21 healthy, adult male volunteers in an eight-way crossover trial."( Short report: a comparative study of the interaction between antacid and H2-receptor antagonists.
Bachmann, KA; Jauregui, L; Levine, L; Miller, K; Reese, JH; Sullivan, TJ, 1994
)
0.49
" Comparison of the parenteral and enteral potencies indicated that FRG-8813 has a lower bioavailability than famotidine and cimetidine in rats and dogs."( Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs.
Chida, Y; Inaba, N; Ohnishi, H; Onodera, S; Shibata, M; Yamaura, T, 1993
)
0.5
" Future studies with famotidine in paediatrics should address its disposition in children under the age of 1 year and in children with compromised renal function, as well as the bioavailability of the oral formulation."( Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.
James, LP; Kearns, GL, 1996
)
0.88
" The results of these studies indicate that neither food nor the elevation of gastric pH influence the absorption or bioavailability of grepafloxacin."( Effect of food and gastric pH on the bioavailability of grepafloxacin.
Bramer, SL; Efthymiopoulos, C; Maroli, A, 1997
)
0.3
"This study was designed to determine the influence of aluminum hydroxide and famotidine on the bioavailability of tosufloxacin."( Effects of aluminum hydroxide and famotidine on bioavailability of tosufloxacin in healthy volunteers.
Inotsume, N; Minami, R; Nakamura, C; Nakano, M, 1998
)
0.81
" The bioavailability determined from comparison of intravenous and oral area under the curve data was 71% +/- 27%."( Pharmacokinetics of famotidine in patients with cystic fibrosis.
Farrar, HC; Kearns, GL; Letzig, LG; Maish, WA; McCubbin, MM, 1998
)
0.62
" Approximate dose-proportionality, no accumulation on multiple dosing and an estimated bioavailability similar to adult values were also observed."( Pharmacokinetics of famotidine in infants.
Baier, J; Blumer, JL; Eisenhandler, R; James, LP; Kearns, GL; Marshall, JD; Murphy, MG; Panebianco, DL; Scheimann, AO; Wenning, LA; Yeh, KC; Zhong, L, 2005
)
0.65
"Famotidine, a histamine-2 blocker with good bioavailability in the presence of food, would reduce the incidence and severity of exercise-induced gastric disease in sled dogs."( Efficacy of famotidine for the prevention of exercise-induced gastritis in racing Alaskan sled dogs.
Davis, MS; McKenzie, EC; Payton, ME; Royer, CM; Willard, MD; Williamson, KK,
)
1.95
"5 and 20 times more potent than ranitidine and cimetidine, respectively, its oral bioavailability is low and variable; due mainly to its poor aqueous solubility."( Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
Fahmy, RH; Kassem, MA, 2008
)
0.7
" Furthermore, an in vivo study in rats showed that the microspheres neither decrease the bioavailability nor retard the release of famotidine significantly."( Taste masking microspheres for orally disintegrating tablets.
Bovet, LL; Xu, J; Zhao, K, 2008
)
0.55
"Most of the floating systems have an inherent drawback of high variability in the GI transit time, invariably affecting the bioavailability of drug."( Floating controlled drug delivery system of famotidine loaded hollow microspheres (microballoons) in the stomach.
Dhanaraju, MD; Ramachandran, S; Shaheedha, SM; Thirumurugan, G, 2010
)
0.62
"The objective of the present study was to evaluate the potential influence of carboxymethyl-beta-cyclodextrin (CM-beta-CyD) on the aqueous solubility, chemical stability and oral bioavailability of famotidine (FMT) as well as on its bitter taste."( Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
Abou-Taleb, AE; Anraku, M; Hirayama, F; Iohara, D; Khaled, KA; Mady, FM; Otagiri, M; Taguchi, K; Uekama, K; Yamasaki, K, 2010
)
0.75
" The antiulcerogenic effects of erythropoietin may be related to its intrinsic ability to sustain the activities of free-radical scavenging enzymes and the bioavailability of glutathione."( The role of erythropoietin in the protection of gastric mucosa from indometacin-induced gastric injury and its relationship with oxidant and antioxidant parameters in rats.
Albayrak, F; Albayrak, Y; Bayir, Y; Dursun, H; Halici, Z; Koc, F; Odabasoglu, F; Polat, B; Suleyman, H; Uyanik, A, 2010
)
0.36
" Since such reduction in exposure can lead to significant loss of efficacy, it is imperative to (1) understand the behavior of the compound as a function of stomach pH to inform of any risk of bioavailability loss in clinical studies and (2) develop a robust formulation which can provide adequate exposure in achlorhydric patients."( Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development.
Kesisoglou, F; Mitra, A, 2013
)
0.39
"Famotidine HCl has low bioavailability (40-45%) due to its narrow absorption window and low solubility in intestinal pH."( Design and development of novel lipid based gastroretentive delivery system: response surface analysis, in-vivo imaging and pharmacokinetic study.
Ahmed Abdelbary, A; Elsayed, I; Hassen Elshafeey, A, 2015
)
1.86
"Abstract The aims of this study were to prepare fine famotidine-containing floating-bioadhesive cooperative minitablets and to investigate the possibility of using those minitablets as a delivery system for promoting the oral bioavailability of famotidine."( Preparation of multiple-unit floating-bioadhesive cooperative minitablets for improving the oral bioavailability of famotidine in rats.
Li, X; Qi, X; Wu, Z; Xing, J; Zhang, Z; Zhu, X, 2014
)
0.86
"The aim of this study was to prepare a disintegrating gastric floating tablet composed of floating pellets coated with acrylic resin to prolong the gastric residence time and increase the oral bioavailability of famotidine."( Tablets compressed with gastric floating pellets coated with acrylic resin for gastro retention and sustained release of famotidine: in-vitro and in-vivo study.
Jiang, Y; Qi, X; Wu, Z; Zhang, H, 2015
)
0.81
"43 h ng/ml), while the relative bioavailability was 187."( Tablets compressed with gastric floating pellets coated with acrylic resin for gastro retention and sustained release of famotidine: in-vitro and in-vivo study.
Jiang, Y; Qi, X; Wu, Z; Zhang, H, 2015
)
0.62
" Interestingly, famotidine increased the estimated bioavailability of metformin [cumulative amount of unchanged drug excreted in urine from time zero to infinity (A e∞)/dose; p < 0."( The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
Brett, CM; Castro, RA; Giacomini, KM; Goswami, S; Hibma, JE; Huang, Y; Keizer, RJ; Savic, RM; Stocker, SL; Wittwer, MB; Yee, SW; Zhang, X; Zur, AA, 2016
)
1.14
"These results suggest that famotidine may improve the bioavailability and enhance the renal clearance of metformin."( The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
Brett, CM; Castro, RA; Giacomini, KM; Goswami, S; Hibma, JE; Huang, Y; Keizer, RJ; Savic, RM; Stocker, SL; Wittwer, MB; Yee, SW; Zhang, X; Zur, AA, 2016
)
1.09
" NPs prepared from PLA-g-PEG5% are promising to improve oral bioavailability of P-gp substrates."( Design of PEG-grafted-PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model Famotidine.
Gosselin, P; Hildgen, P; Lacasse, F; Mokhtar, M, 2017
)
0.67
" This phase 1 study in healthy subjects evaluated the relative bioavailability of filgotinib maleate tablets versus the reference tablet (filgotinib hydrochloride) and effects of food and acid-reducing agents (ARAs) on the pharmacokinetics of filgotinib and its major metabolite."( The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Anderson, K; Cuvin, J; Kotecha, M; Namour, F; Qin, AR; Scott, B; Sharma, S; Xin, Y; Zheng, H, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Famotidine (FM) is considered among the first-line therapy for treatment of gastric ulcers; however, its poor aqueous solubility resulted in low bioavailability and limited therapeutic efficacy."( Soluplus
Basha, M; Noshi, SH; Salama, A, 2020
)
2
" This degradation pathway is a probable major reason for the poor bioavailability of FAM."( Pentabromobenzyl-RP versus triazole-HILIC columns for separation of the polar basic analytes famotidine and famotidone: LC method development combined with in silico tools to follow the potential consequences of famotidine gastric instability.
Belal, F; El-Shaheny, R; Radwan, MO; Yamada, K, 2020
)
0.78
"Famotidine (FMT) an anti-ulcer drug, recently being repurposed in COVID-19 treatment, suffers from poor aqueous solubility and restricted bioavailability (<40%)."( Pharmaceutical Cocrystals of Famotidine: Structural and Biopharmaceutical Evaluation.
Chadha, K; Chadha, R; Dhingra, N; Dureja, J; Jindal, A; Karan, M; Prashar, M, 2022
)
2.46
" The studies show that complexation with famotidine or ranitidine may affect the bioavailability of sparfloxacin."( Simultaneous interaction, degradation, and kinetic study of sparfloxacin with H2 receptor antagonist.
Amir Hassan, -; Fouzia Shafi, -; Iffat Sultana, -; Maria Qureshi, -; Nazia Tabassum, -; Qurat Ul Aen Ismail, -; Sadia Iqbal, -; Shereen, -; Sohail Hassan, -; Tahreem Mujtaba, -, 2023
)
1.18
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56

Dosage Studied

The dosage of gastrosidin (famotidine) was reduced to 40 mg a day only if side effects appeared: diarrhea (4) and urticaria (3). Both famotidine regimens resulted in a significantly greater proportion of patients with complete endoscopic healing than placebo.

ExcerptRelevanceReference
" There was no significant difference of integrated 6-h plasma ethanol concentration, peak ethanol concentration, or time to reach peak ethanol concentration after dosing with either ranitidine, cimetidine or famotidine or placebo."( Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal.
Fraser, AG; Hudson, M; Pounder, RE; Rosalki, SB; Sawyerr, AM; Smith, M, 1992
)
0.78
" dosing of this selective compound is necessary for achieving adequate results."( Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp, IC, 1992
)
1.73
" The effective dosage and the method and timing of administration remain unclear."( [Therapeutic control of premedication with famotidine given on the evening before surgery for the prevention of pneumonitis in heart surgery patients].
Adt, M; Heim, J; Hetzer, R; Hummel, M; Müller, V, 1992
)
0.55
" However, many authors report that an H2RA resistant ulcer can be cured by increasing the dosage of H2RA, or using another H2RA."( Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai, K, 1992
)
0.28
" While very safe, clinicians need to know correct dosing guidelines, drug interactions, and side effect profiles."( The clinical use of histamine-2 receptor antagonists.
Michocki, RJ; Richardson, JP, 1992
)
0.28
" A statistically significant rise in nocturnal acidity was observed after all regimens, except after dosing with famotidine."( Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.
Nwokolo, CU; Pounder, RE; Sawyerr, AM; Smith, JT, 1991
)
0.49
" Both famotidine regimens resulted in a significantly greater proportion of patients with complete endoscopic healing than placebo, with the BID dosing being numerically superior to the 40-mg HS dose."( Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
Berlin, RG; Bradstreet, DC; Humphries, TJ; Sabesin, SM; Walton-Bowen, KL; Zaidi, S, 1991
)
2.2
" Since its clearance is reduced in patients with renal insufficiency and in elderly patients, the maintenance dosage should be reduced in these patient groups."( Clinical pharmacokinetics of famotidine.
Echizen, H; Ishizaki, T, 1991
)
0.57
" Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief."( Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991
)
1.72
" We conducted a randomized single-blind study on the effects of 1 g sucralfate four times daily (n = 8), a mucosa-protective agent, versus 40 mg famotidine twice daily (n = 8), a new H2-blocker agent, administered for 12 weeks, in the treatment of peptic esophagitis (grades I to IV in accordance with Savary and Miller) refractory to a 6-month therapy with ranitidine at a dosage of 150 or 300 mg twice daily."( Failure of sucralfate in the treatment of refractory esophagitis versus high-dose famotidine. An endoscopic study.
Bianchi Porro, G; Lazzaroni, M; Pace, F, 1991
)
0.71
" Since nocturnal dosing with famotidine 20 mg is effective in preventing gastric ulcer relapse over a 1-year period and is well tolerated, it offers a therapeutic option for the long-term treatment of patients with gastric ulcer."( Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer.
Berlin, RG; Cook, TJ; Root, JK, 1991
)
0.88
" Each group had a control study and a repeat study after 7 days dosing with either placebo or an H2-receptor antagonist (300 mg ranitidine nocte, 800 mg cimetidine nocte, or 40 mg famotidine nocte)."( The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption.
Fraser, AG; Hudson, M; Pounder, RE; Prewett, EJ; Rosalki, SB; Sawyerr, AM, 1991
)
0.74
"The acid-inhibitory action of H2-receptor antagonists was shown to decrease after one to two weeks of dosing in healthy volunteers."( Tolerance to oral H2-receptor antagonists.
Ernst, T; Gennoni, M; Halter, F; Merki, HS; Wilder-Smith, CH; Zeyen, B, 1990
)
0.28
"This study was designed to establish appropriate dosing requirements for intravenous use of famotidine, a new H2-receptor antagonist, in pediatric patients."( Suppression of gastric acid secretion by intravenous administration of famotidine in children.
Davis, PM; Hyams, JS; Treem, WR, 1991
)
0.73
" No significant increases were observed in plasma trough famotidine concentrations following multiple oral dosing in any of the subjects, and the kinetic variables after the seventh dose were not significantly different from those following the single oral dose."( Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
Cottrell, J; Mann, SG; Morgan, MY; Stambuk, D, 1990
)
0.85
" Based on a number of considerations--chemical structure, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, and dosage regimen--famotidine represents an end-point in the development of the H2-antagonist group of anti-ulcer agents."( Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview.
Dammann, HG, 1990
)
0.8
" All volunteers responded to famotidine but dosage requirements varied (range 41 mg to 126 mg)."( Use of automatic computerised pump to maintain constant intragastric pH.
Chesner, I; Hannan, A; Mann, S; Merki, HS; Walt, RP, 1990
)
0.57
" Omeprazole caused a non-competitive inhibition of the dose-response curve to dimaprit, whereas famotidine induced a parallel shift to the right without depressing the maximum response."( Antisecretory activity of omeprazole in the conscious gastric fistula cat: comparison with famotidine.
Bertaccini, G; Coruzzi, G,
)
0.57
" No changes in DNA synthesis, percentage of labelled nuclei and transaminase were detected when the agents were added to the hepatocytes in culture at concentrations within the effective pharmacological dosage and 30 times higher."( Effect of cimetidine, ranitidine, famotidine and omeprazole on hepatocyte proliferation in vitro.
Amoruso, A; Barone, M; Di Leo, A; Francavilla, A; Ingrosso, M; Makowka, L; Panella, C; Polimeno, L; Starzl, TE, 1989
)
0.56
" Famotidine was well-tolerated and no serious clinical or laboratory adverse effects were judged to be related to this dosing regimen of famotidine."( Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing.
Graham, DY; Knuff, TE; Lanza, FL; Levenson, HL; Lyon, DT; McCullough, AJ; Munsell, WP; Perozza, J; Roufail, WM; Sinar, DR, 1989
)
1.45
"A multicentre, randomized, double-dummy control trial compared the efficacy of two famotidine dosage regimens for the treatment of acute gastric mucosal lesions."( Clinical evaluation of 20 mg/day famotidine in the treatment of acute gastric mucosal lesions.
Miwa, T, 1989
)
0.78
" The therapy was prolonged for two years with the same dosage at the beginning and later with half doses without any relapse and secondary effects."( [Duodenal ulcer, study of gastric secretion and rational treatment with famotidine in different doses].
Idotta, G; Morucci, P; Santoro, E; Scutari, F, 1989
)
0.51
" Pentagastrin-stimulated acid secretion remained decreased (50% of control) 12 hr after oral dosing with 20 mg famotidine."( Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.
Chremos, AN; Gamal, MA; Graham, DY; Smith, JL, 1985
)
1.92
" Omeprazole, in contrast, did not alter gastric emptying at a similar antisecretory dosage level."( Effects of H2-receptor antagonists upon physiological acid secretory states in animals.
Cook, PG; Mangel, AW; Pendleton, RG; Shepherd-Rose, A, 1985
)
0.27
" Minimal toxicologic effects (after acute, subacute, or chronic administration) have been observed even at extremely high dosage levels (4,000 mg/kg/day) and for extended periods of administration (2,000 mg/kg/day for 105 weeks)."( Famotidine: summary of preclinical safety assessment.
Bokelman, DL; Burek, JD; Majka, JA, 1985
)
1.71
" Elimination of these model drugs was studied before and during 8 days of famotidine dosing in 8 healthy volunteers."( Effect of famotidine on oxidative drug metabolism.
Kitchingman, GA; Langman, MJ; Somerville, KW, 1986
)
0.9
" Patients received either ranitidine (150 mg twice daily) or famotidine at one of three different dosage regimens: 40 mg at bedtime, 40 mg twice daily, or 20 mg twice daily."( A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease.
McCullough, AJ, 1986
)
0.76
" Maximal effect is achieved by the 40-mg dose, with peak activity reached one to three hours after dosing and a duration of action lasting 10 to 12 hours."( Pharmacodynamics of famotidine in humans.
Chremos, AN, 1986
)
0.59
" Gastric acid hypersecretion was controlled in seven patients with less frequent dosing with famotidine than with cimetidine or ranitidine."( Famotidine in the therapy of gastric hypersecretory states.
Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; Slaff, JI; Vinayek, R; Wank, SA, 1986
)
1.93
" However, when the preparations were precontracted with histamine (10(-5)M), dose-response curves for relaxation were shifted to the right, and low-concentrations of all three histamine H2-antagonists augmented histamine-induced tone."( Direct effects of H2-receptor antagonists on airway smooth muscle and on responses mediated by H1- and H2-receptors.
Hashimoto, Y; Iwatsuki, N; Koga, Y, 1987
)
0.27
"32 mumol kg-1 h-1) caused a parallel displacement of the dose-response curve to dimaprit to the right, without reducing the maximum response to the stimulant, thus behaving as a competitive antagonist, like ranitidine."( Inhibitory effect of famotidine on cat gastric secretion.
Bertaccini, G; Coruzzi, G; Dobrilla, G; Noci, MT, 1986
)
0.59
"7% of the patients in the 10- and 20-mg dosage groups, respectively, did not have evidence of erosions or hemorrhages, compared with 73% of patients in the 5-mg group."( Famotidine in the treatment of gastritis.
Miwa, T; Miyoshi, A, 1987
)
1.72
" These results support the effectiveness of a 12 hour or possibly a 24-hour dosing interval for famotidine."( Effect of a histamine H2-receptor antagonist, famotidine, on gastric secretion in healthy subjects.
Fukuda, Y; Ikezoe, I; Ohama, I; Okabayashi, M; Shimoyama, T, 1987
)
0.75
" No reduction in drug dosage should therefore be necessary in these patients."( Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan, MY; Stambuk, D, 1986
)
1.71
" Since famotidine is essentially free of dose-related adverse effects, dose adjustment in patients with mild renal insufficiency and in elderly people is not required; however, either a prolonged dosing interval or a decrease in daily dose during long-term therapy may be adapted for the patients with severe renal insufficiency to avoid accumulation and the potential undesirable effects."( Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
Antonello, J; Chremos, AN; Hessey, GA; Lin, JH; Yeh, KC, 1988
)
0.96
" These data are at variance with those previously published, and the slight effect of the single nightly doses of H2 blockers on daytime acidity seems to confirm further that the suppression of nocturnal acidity may really be the decisive factor in the success of this dosing schedule in treating duodenal ulcer."( Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring.
Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988
)
0.27
" Therefore, the two dosing schedules of each H2 antagonist increased intragastric pH differently, but both the half and the standard large regimens produced similar overnight virtual anacidity."( Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988
)
0.27
" Therefore, the same dosage schedule as in uraemia may be applied in patients with dialysis."( Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
Brockmeier, D; Lameire, N; Rosenkranz, B, 1988
)
0.27
" In contrast to cimetidine, basal and pentagastrin-stimulated gastric acid secretion measured 12 h after dosing was significantly inhibited during treatment with famotidine."( A comparison of the effects of treatment with either famotidine 40 mg or cimetidine 800 mg nocte on gastric acid secretion and serum gastrin.
Crean, GP; Fullarton, GM; Laferla, G; McColl, KE, 1988
)
0.72
" dosing regimen with famotidine in order to achieve optimal mucosal healing and day time symptom control."( Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.
Antonello, J; Cagliola, A; Humphries, TJ; Orr, WC; Robinson, MG, 1988
)
0.9
" This single evening dosage regimen produces effective healing of gastric and duodenal ulceration; maintenance of healing can then be achieved satisfactorily with 20 mg in the evening."( The place of famotidine in anti-ulcer therapy.
Mann, SG, 1987
)
0.64
" The efficacy of famotidine was examined in three oral dosing regimens--20 mg BID, 40 mg HS, and 40 mg BID."( Famotidine in the management of duodenal ulcer: an analysis of multicenter findings worldwide.
Reynolds, JC, 1988
)
2.06
"0005) but the effects of either dosage were similar."( Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer.
Kaufman, D; Kempf, M; Merki, HS; Neumann, J; Röhmel, J; Walt, RP; Witzel, L, 1988
)
0.55
" The convenient dosage regimen of famotidine (one tablet in the evening) should improve patient compliance, which, in turn, may result in faster healing of ulcers and a lower incidence of ulcer complications."( Famotidine: proven once-a-day treatment for gastric ulcer.
Dammann, HG; Hentschel, E; Muller, P; Simon, B; Walter, TA, 1987
)
1.99
" These data indicate that dosage adjustment may be necessary in patients who have renal insufficiency."( Disposition of famotidine in renal insufficiency.
Abraham, PA; Chremos, AN; Halstenson, CE; Keane, WF; Matzke, GR; Opsahl, JA, 1987
)
0.63
" The expected antisecretory effect of a particular dosage regimen in patients with duodenal ulcer can be predicted mathematically from data derived from studies in normal volunteers."( Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.
Burget, DW; Howden, CW; Hunt, RH; Jones, DB, 1986
)
0.27
"A famotidine wafer that rapidly disperses on the tongue without water is a novel alternative to other histamine2 (H2)-antagonist dosage forms."( Novel oral medication delivery system for famotidine.
Berger, ML; Bjornsson, TD; Ebel, DL; Han, R; Hoover, ME; Schwartz, JI; Stauffer, LA; Tomasko, L; Yeh, KC, 1995
)
1.28
" These results indicate that lansoprazole at a dosage of 30 mg once daily in the morning produced the most potent inhibition of acid secretion in young Japanese volunteers, compared with famotidine 20 mg twice daily and omeprazole 20 mg once in the morning."( Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Asaka, M; Hokari, K; Takeda, H, 1995
)
0.48
" Dosage requirements vary according to age and clinical condition, and children require a relatively higher drug dosage (mg/kg) than adults."( Do H2 receptor antagonists have a therapeutic role in childhood?
Kelly, DA, 1994
)
0.29
" The maximum plasma concentration and the time to peak concentration after oral dosing were also unaffected."( Effect of famotidine on ciprofloxacin pharmacokinetics after single intravenous and oral doses in rats.
al-Khamis, KI; Ashour, LF; Bawazir, SA; el-Sayed, N; el-Sayed, YM; Jim, LK, 1994
)
0.69
" Moreover, the inhibitory effect of YM-14471 was more prolonged than those of famotidine and cimetidine by either route, and it was as long as that of omeprazole dosed orally."( Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs.
Fujihara, A; Kamato, T; Miyata, K; Nishida, A; Takeda, M; Yuki, H, 1993
)
0.51
" We conclude that gastric mucosal concentrations of histamine H2-receptor blockers achieved after oral dosing are probably too low to cause significant inhibition of gastric ADH in vivo."( Inhibition of gastric alcohol dehydrogenase activity by histamine H2-receptor antagonists has no influence on the pharmacokinetics of ethanol after a moderate dose.
Bergmann, JF; Blanc, LE; Delchier, JC; Dhumeaux, D; Dutreuil, C; Mallat, A; Roudot-Thoraval, F; Simonneau, G; Trout, H, 1994
)
0.29
" The inclusion of oral and intravenous dosage data of alcohol is mandatory to positively identify first-pass metabolism in any individuals."( H2-antagonists and alcohol. Do they interact?
Gugler, R, 1994
)
0.29
" The YM022 dosage required in this model was much greater than that required in the inhibition of gastric acid."( YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Akuzawa, S; Ito, H; Kamato, T; Kobayashi, A; Miyata, K; Nagakura, Y; Nishida, A; Takinami, Y; Yamano, M; Yuki, H, 1994
)
0.29
" In 3 patients the dosage of famotidine was gradually reduced without any symptoms."( [Gastrocystoplasty in adults and postoperative aciduria].
Kato, H; Kontani, K; Muraishi, O; Ogawa, A; Tsuruta, T; Yamashita, T, 1994
)
0.58
" In the dosage of 40 mg (bedtime once, or daily twice) significantly decreases the basal and the stimulated gastric acid secretion as well as the daily and the nocturnal pains of the patients."( [Famotidine in the treatment of gastroduodenal ulcer].
Fehér, J; Lengyel, G, 1994
)
1.2
"The application of LC-MS to characterize low-level degradates in pharmaceutical dosage formulations is a new and challenging field."( Pharmaceutical application of LC-MS. 1--Characterization of a famotidine degradate in a package screening study by LC-APCI MS.
Brooks, MA; Chang, KH; Dradransky, PM; Ip, DP; Qin, XZ; Sakuma, T, 1994
)
0.53
" The subjects consumed 50 g alcohol after a standard lunch on the eighth day of dosing with study medication."( Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime.
Braithwaite, R; Gibson, GJ; Hale, KA; Kendall, MJ; Langman, MJ; Spannuth, F; Walt, RP, 1994
)
0.29
" Twelve healthy male volunteers received each of 4 dosing regimens: 200 mg itraconazole alone, 200 mg itraconazole and famotidine, 100 mg fluconazole alone, and 100 mg fluconazole and famotidine."( Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity.
Hudson, M; Lim, SG; Pounder, RE; Sawyerr, AM; Sercombe, J, 1993
)
0.49
" In addition to the patient's age and the prescriber's medical specialty, specific DUE criteria included the reason given in the medical record for use; dosage regimen and adjustments made on the basis of the patient's renal function; other GI drugs taken concurrently; pharmacist intervention; simultaneous use of oral medications; occurrence of adverse events; H2-antagonist use with specified drug products known to affect serum drug concentrations of one or both medications; and use of gastric pH monitoring."( Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
Ben-Joseph, R; Oh, T; Russell, WL; Segal, R, 1993
)
0.55
" We reexamined the difference in gastric acidity and volume in inpatients and outpatients, and tested the effectiveness of different oral doses and dosage regimens of famotidine in reducing gastric acidity and volume in both groups of patients."( Dose-response study of oral famotidine for reduction of gastric acidity and volume in outpatients and inpatients.
Solanki, DR; Talke, PO, 1993
)
0.77
" The only risk factor for ranitidine was for patients who did not have their dosage corrected for renal function ("overdose"); these patients were twice as likely to experience a PADR compared with patients who received the correct dosage as determined by their renal function."( Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.
Ben-Joseph, R; Russell, WL; Segal, R, 1993
)
0.29
" A standardized dosage of cyclosporine was given orally, and the duration was calculated for the maximum whole blood level of cyclosporine to be achieved; the dosage/level quotient was calculated."( The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results.
Markewitz, A; Meiser, BM; Muschiol, F; Nollert, G; Pfeiffer, M; Reichart, B; Reichenspurner, H; Uberfuhr, P; Wagner, F,
)
0.13
"The dose-response relationship of oral famotidine at doses up to 10 mg was evaluated in 10 healthy male subjects to assess the extent and duration of inhibition of meal-stimulated intragastric acid secretion."( Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trial.
Laskin, OL; Lasseter, KC; Patterson, PM; Shamblen, EC; Shingo, S, 1993
)
0.81
"4 mg/kg as an intravenous infusion over 5 min (a dosage previously used to test drug interactions with cimetidine and ranitidine) were evaluated in 7 patients with chronic obstructive pulmonary disease (COPD) and peptic ulcer disease before and after 8 days' treatment with famotidine 40mg at night."( Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.
Dal Negro, R; Pomari, C; Turco, P, 1993
)
1.91
" In the guinea pig ileum, millimolar concentrations of cimetidine and famotidine shifted the dose-response curve of the contractile response to acetylcholine rightward."( Comparative effects of cimetidine and famotidine on the vagally stimulated acid secretion in the isolated mouse whole stomach.
Kanaoka, S; Watanabe, K; Yamamoto, M; Yano, S, 1993
)
0.79
" Our results indicate that the omeprazole dosage to be used in the treatment of Zollinger-Ellison syndrome must be chosen principally on the basis of basal acid secretion determination."( Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.
Annibale, B; Cassetta, MR; Corleto, V; D'Ambra, G; Delle Fave, G; Ferrua, B; Saggioro, A, 1993
)
0.29
"To determine whether, in a susceptible population, dosing with 10 mg famotidine 1 h before an evening meal could decrease the interference with sleep caused by heartburn."( Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal.
Cottrell, J; Mann, SG; McCarroll, K; Mehentee, J; Morton, R; Murakami, A; Rao, AN, 1995
)
0.94
" These observations suggest that a large dosage of OMP suppresses liver regeneration, while FAM appears to have no meaningful effect on regeneration."( The liver regenerative response elicited by antisecretory agents in partially hepatectomized rats: a comparison between omeprazole and famotidine.
Aono, T, 1995
)
0.49
"6 h) dosing periods."( Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men.
Collier, DS; McGuire, TR; Rossi, SJ; Schaaf, LJ; Shaefer, MS; Stratta, RJ, 1995
)
0.53
" This multicenter, randomized, double-masked, placebo-controlled trial, conducted in the United States, examined whether two famotidine dosing regimens are effective in extending the time in remission for patients with moderate-to-severe erosive esophagitis."( Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.
Berlin, RG; Berman, RS; Hayden, LJ; Reagan, JE; Roberts, WG; Simon, TJ,
)
0.66
" In that study, the maximal dosage of famotidine was limited to 40 mg/day, the recommended maximal dosage for the treatment of peptic ulcer disease."( An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.
Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Prell, GD; Rosenberg, P; Rosse, RB; Tsui, LC; Wyatt, RJ, 1996
)
0.81
" The YM022 dosage required to inhibit basal acid secretion is consistent with that required to suppress pentagastrin-induced acid secretion."( Comparative evaluation of the role of endogenous gastrin in basal acid secretion in conscious rats provided with chronic fistula and pylorus ligation.
Akuzawa, S; Miyata, K; Nishida, A; Takemoto, Y; Uchida-Kobayashi, A, 1996
)
0.29
"Rats were dosed with famotidine, omeprazole, or buffer control for 4 weeks."( The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach.
Boland, CR; Delbarre, SG; Kraus, E; Yoshimura, K, 1996
)
0.9
" Total glycoprotein synthesis was inhibited at all times by omeprazole, but only after the cessation of dosing with famotidine."( The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach.
Boland, CR; Delbarre, SG; Kraus, E; Yoshimura, K, 1996
)
0.79
"Twenty-four healthy subjects were dosed with either famotidine 10 mg, ranitidine 75 mg or placebo in a balanced three-period cross-over design."( Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996
)
0.82
" During the late period (7-9 h post-dose), when the subjects were dosed with placebo, mean gastric acid output was 41."( Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996
)
0.57
" In conclusion, a dosage of 600 mg/d of ACZ has shown to be as effective as 40 mg/d of FMT in the healing of duodenal ulcer."( [A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)].
Arenas, JI; Belda, O; de la Santa, Jw; Diago, A; Domínguez, A; Fernández, C; García-Plaza, A; Martín, L; Pallarés, A; Rodrigo, L, 1996
)
0.54
"30 h and were dosed (at 19."( Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo.
Cottrell, J; Grimley, CE; Mann, SG; Nwokolo, CU; Stauffer, L, 1997
)
0.54
" Comparisons of mean AUCs for each 15 min period after dosing showed that decrease in acidity was significantly greater after cimetidine 200 mg effervescent than after famotidine 10 mg for the first 60 min."( Low-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight pH study.
Cottrell, J; Grimley, CE; Mann, SG; Nwokolo, CU; Raskin, S; Reilly, TG; Usselmann, B, 1998
)
0.91
"Inhibition of gastric acidity over the 12 h post-dose period was significantly greater and endured longer after famotidine 10 mg than after effervescent cimetidine 200 mg, but for the 60 min period immediately after dosing the effect on intragastric pH was significant following effervescent cimetidine 200 mg but not famotidine 10 mg."( Low-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight pH study.
Cottrell, J; Grimley, CE; Mann, SG; Nwokolo, CU; Raskin, S; Reilly, TG; Usselmann, B, 1998
)
0.93
" The authors' five cases and the other seven previously reported emphasize the need for dosage adjustment of famotidine in elderly patients and in those with renal failure, and that these patients should be carefully monitored for development of central nervous system reactions, which sometimes could be very serious."( Central nervous system reactions associated with famotidine: report of five cases.
Odeh, M; Oliven, A, 1998
)
0.77
"In a 1400-bed teaching hospital, an audit (by specially trained personnel) was conducted to monitor inpatient prescribing of omeprazole (1) in preference to H2-antagonists and other drugs according to agreed criteria (Helicobacter pylori eradication, severe reflux esophagitis, rapid ulcer healing deemed urgent because of severe symptoms or complications, high-dose steroid therapy of > or =30 mg/day prednisolone) and (2) appropriateness of intravenous dosing (oral route not feasible or contraindicated)."( Antiulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback".
Chan, CK; Cheung, E; Ching, TY; Chu, KM; Kong, Y; Kou, M; Kumana, CR; Lam, SK; Seto, WH, 1998
)
0.3
" cimetidine or famotidine for stress ulcer prophylaxis were reviewed during a two-month period in 1997, and information on demographics, dosage and duration of H2RA therapy, admission date, laboratory test values, and adverse drug reactions was collected."( Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists.
Blayney-Chandramouli, J; McCoy, S; Mutnick, A, 1998
)
0.65
" The time to onset of action and the degree of gastric acid inhibition of the H2 -RAs famotidine and cimetidine at dosage levels approved for over-the-counter use (10 mg famotidine and 200 mg cimetidine) were compared."( The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration.
Decktor, D; Houle, JM; Pierce, CH, 1998
)
0.85
" Forty hospitals provided data about purchase prices for each IV H2-RA dosage form purchased (cimetidine, ranitidine, and famotidine), the number of each dosage form used during the 12-month study period, purchase price and extent of usage for supplies, labor costs for preparing and administering IV H2-RAs, and IV H2-RA dosage schedules."( A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
Ben-Joseph, R; Oh, T; Russell, WL; Segal, R, 1994
)
0.5
"The aim of this study was to compare the direct medical costs associated with the treatment of patients with heartburn/nonulcer dyspepsia under 2 scenarios: (i) no nonprescription histamine H2 receptor antagonist (H2RA) is available (the 'status quo scenario'); and (ii) the H2RA famotidine (at a daily dosage of 10mg) is available over-the-counter (OTC) at retail pharmacies (the 'OTC scenario')."( Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
Goeree, R; Henke, CJ; O'Brien, BJ; Tasch, RF, 1996
)
0.73
" This newly developed capillary electrophoresis (CE) method was applied for the determination of analytes extracted from plasma taken from a volunteer dosing a cimetidine, ranitidine, and nizatidine tablet simultaneously."( Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma.
Chen, SH; Ho, YH; Ko, HS; Wu, HL; Wu, SM, 2001
)
0.52
"Healthy subjects (12 male, 12 female) were dosed on three occasions with single oral doses of placebo, ranitidine, 75 mg, and famotidine, 10 mg, 1 h after lunch."( Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton, MI; Pounder, RE; Sercombe, J, 2001
)
0.75
"5-h period following dosing (4."( Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton, MI; Pounder, RE; Sercombe, J, 2001
)
0.54
"Quantitative determination of famotidine and its dosage forms was carried out spectrophotometrically, analysing the coloured complex resulting from a charge-transfer interaction between the drug as an electron-donor and chloranilic acid as an electron-acceptor."( Quantitative determination of famotidine through charge-transfer complexation with chloranilic acid.
Ajali, U; Chukwurah, BK,
)
0.71
" Nocturnal acid breakthrough occurs on any dosing regimen of oral proton pump inhibitors."( Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors.
Ahmed, F; Castell, DO; Katz, PO; Korn, S; Tutuian, R, 2002
)
0.31
"Assess intragastric acid control on omeprazole, 20 mg, taken every morning, after variable dosing of over-the-counter famotidine, 10 mg."( Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors.
Ahmed, F; Castell, DO; Katz, PO; Korn, S; Tutuian, R, 2002
)
0.52
" Adjusting the maintenance dosage of H(2)-histamine antagonists has been recommended in elderly patients since age-related reduction in renal plasma flow, glomerular filtration rate and renal tubular function may be present, which can in turn elevate histamine levels in plasma and cerebrospinal fluid."( H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures.
Bergemann, N; Diebold, K; Mundt, C; Roesch-Ely, D; Sartor, K; von Einsiedel, RW, 2002
)
0.61
" The proposed method was used successfully for stability testing of the pure drugs in the presence of up to 90% of their degradates, in bulk powder and dosage forms."( Determination of cimetidine, famotidine, and ranitidine hydrochloride in the presence of their sulfoxide derivatives in pure and dosage forms by high-performance thin-layer chromatography and scanning densitometry.
Aziz, AM; Farrah, LA; Hegazy, MA; Kelani, KM,
)
0.42
" The dosage of gastrosidin (famotidine) was reduced to 40 mg a day only if side effects appeared: diarrhea (4) and urticaria (3)."( [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Li, IA; Vasil'ev, IuV, 2002
)
0.91
" It was concluded that the pharmacokinetics of famotidine are significantly altered in children with chronic renal insufficiency; accordingly, dosing should be based on glomerular filtration rate (i."( Famotidine disposition in children and adolescents with chronic renal insufficiency.
Blumer, JL; Hak, EB; James, LP; Jones, DP; Kearns, GL; Maples, HD; Stowe, CD; Vogt, B; Wells, TG; Wilson, JT, 2003
)
2.02
" The suggested procedures could be used for the determination of trazodone, famotidine, and diltiazem, both in pure and dosage forms without interference from common excipients."( New colorimetric methods for the determination of trazodone HCl, famotidine, and diltiazem HCl in their pharmaceutical dosage forms.
Abdellatef, HE; Ayad, MM; Hosny, MM; Shalaby, A, 2003
)
0.79
"0 mg/kg may be more efficacious in some, the dosage may require individualization based on response."( Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.
Ahrens, SP; Czinn, SJ; Devandry, SN; Dice, JE; Liacouras, CA; Orenstein, SR; Shalaby, TM; Simon, TJ; Stauffer, LA, 2003
)
1.76
" A controlled release dosage form of H2 receptor antagonist-like drugs may be beneficial for long-term treatments."( Caco-2 cell culture as a model for famotidine absorption.
Abbasoglu, U; Degim, Z; Essiz, D; Unal, N,
)
0.41
" Approximate dose-proportionality, no accumulation on multiple dosing and an estimated bioavailability similar to adult values were also observed."( Pharmacokinetics of famotidine in infants.
Baier, J; Blumer, JL; Eisenhandler, R; James, LP; Kearns, GL; Marshall, JD; Murphy, MG; Panebianco, DL; Scheimann, AO; Wenning, LA; Yeh, KC; Zhong, L, 2005
)
0.65
"A concomitant dosage regimen of a histamine 2 receptor antagonist with a proton pump inhibitor (PPI) effectively decreases the incidence of nocturnal acid breakthrough, which is one of the problems encountered when acid-related diseases are treated with a PPI alone."( Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Nakamura, A; Ohashi, K; Shirai, N; Sugimoto, M, 2005
)
0.55
"The combination regimen of famotidine plus rabeprazole is more effective for nocturnal acid inhibition in homozygous and heterozygous EMs than the increased dosage regimen of rabeprazole."( Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Furuta, T; Hishida, A; Ishizaki, T; Kajimura, M; Nakamura, A; Ohashi, K; Shirai, N; Sugimoto, M, 2005
)
0.84
" Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks."( Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005
)
0.93
" Subjects underwent EMR with circumferential mucosal incision assisted by submucosal injection of sodium hyaluronate (EMRSH), followed by IV or oral (PO) administration of famotidine at a dosage of 40 mg/day for 2 days."( Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions.
Ajibe, H; Hanatsuka, K; Hirasawa, T; Kawata, H; Kita, H; Osawa, H; Satoh, K; Satoh, Y; Sugano, K; Sunada, F; Sunada, K; Yamamoto, H; Yoshizawa, M, 2005
)
0.52
" Lansoprazole was dosed after breakfast and dinner."( Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta, T; Hishida, A; Kajimura, M; Nakamura, A; Okudaira, K; Shirai, N; Sugimoto, M, 2005
)
0.61
"Famotidine dosage adjustment is required in patients with chronic kidney disease."( Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes.
Hudson, JQ; Nolan, SF; Pentapaty, N; Redmond, AM; Self, T; Weibel, J, 2005
)
2.23
" This method was successfully applied for famotidine assay from pharmaceutical dosage forms."( [UV spectrophotometric assay of famotidine in combination with picrolonic acid, picrolinate].
Apostu, M; Bibire, N; Dorneanu, V,
)
0.68
"A multitier approach was successful in identifying a solid dosage form that minimizes the pH-dependent absorption of this drug candidate."( Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
Badawy, SI; Gray, DB; Hussain, MA; Schuster, AE; Sun, D; Zhao, F, 2006
)
0.33
"Oral dosage of the H2 receptor antagonists, ranitidine and famotidine, has no significant effect on gastric emptying."( Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers.
Amano, Y; Ishihara, S; Kinoshita, Y; Kushiyama, Y; Miyake, T; Ose, T; Sato, S; Takahashi, Y; Yuki, T, 2006
)
0.58
" The proposed method was successfully applied to the determination of the investigated drugs in pure and pharmaceutical dosage forms (recovery was 98."( Spectrophotometric determination of H(2)-receptor antagonists via their oxidation with cerium(IV).
Darwish, IA; Hassan, AI; Hussein, SA; Mahmoud, AM, 2008
)
0.35
" The results indicated that the proposed method could be used for the determination of FMT in commercial dosage forms and as a stability-indicating assay."( Stability indicating method for famotidine in pharmaceuticals using porous graphitic carbon column.
Helali, N; Monser, L, 2008
)
0.63
"Baseline signalment, observation times, and famotidine dosage (in treated cats) were similar among groups."( Risk of hemolytic anemia with intravenous administration of famotidine to hospitalized cats.
de Brito Galvao, JF; Trepanier, LA,
)
0.63
" The method has been successfully applied to the determination of famotidine in commercial dosage forms."( Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals.
Helali, N; Monser, L; Taverna, M; Tran, NT, 2008
)
0.82
" This confirmed that the spray-dry method produced the most appropriate taste-masked particles for fast-disintegrating dosage forms."( Formulation design of taste-masked particles, including famotidine, for an oral fast-disintegrating dosage form.
Itai, S; Kajiyama, A; Kawai, H; Mizumoto, T; Tamura, T, 2008
)
0.59
" Both DSC and XRD suggested loss of famotidine crystallinity upon liquisolid formulation which was further confirmed by SEM indicating that even though the drug existed in a solid dosage form, it is held within the powder substrate in a solubilized, almost molecularly dispersed state, which contributed to the enhanced drug dissolution properties."( Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
Fahmy, RH; Kassem, MA, 2008
)
0.97
"A fast-disintegrating dosage form has been developed as a user-friendly formulation that disintegrates in the mouth immediately."( Formulation design of an oral, fast-disintegrating dosage form containing taste-masked particles of famotidine.
Itai, S; Kajiyama, A; Kawai, H; Mizumoto, T; Tamura, T, 2008
)
0.56
"The regular dosage of cimetidine showed an inhibitory effect on the motility of SO, while famotidine had no obvious effects otherwise."( Choledochoscope manometry about different drugs on the Sphincter of Oddi.
Chen, JZ; Kong, J; Li, ZS; Shi, G; Wang, W; Wu, SD; Zhang, XB, 2008
)
0.57
" The method was applied for the determination of FMT in its dosage forms."( Spectrofluorimetric determination of famotidine in pharmaceutical preparations and biological fluids. Application to stability studies.
el-Brashy, A; el-Enany, N; Kamel, ME; Walash, MI, 2009
)
0.63
"An amalgamation of solid dispersion and cube sugar or sintering technologies was utilized for preparing a high dissolution rate, fast-release dosage form for poorly water soluble drug(s)."( Development of modified dosage form for enhancement of dissolution rate through amalgamation of solid dispersion and cube sugar or sintering technology using famotidine as a model drug.
Gupta, M; Gupta, V; Madan, AK,
)
0.33
" To date there is no expert system available for the formulation of controlled release dosage forms yet."( Design of an expert system for the development and formulation of push-pull osmotic pump tablets containing poorly water-soluble drugs.
Dong, HY; Li, CL; Liang, M; Liu, HF; Pan, WS; Peng, B; Zhang, ZH, 2011
)
0.37
"15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily."( Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
0.57
" The incidence of esophageal mucosal injury was reduced however with concomitant dosing of aspirin and famotidine (26."( Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012
)
0.59
" History of uncomplicated peptic ulcer and frequent dosing were additional factors associated with non-adherence to NSAIDs."( Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients.
Gonzalez, MA; Lanas, A; Polo-Tomás, M; Roncales, P; Zapardiel, J, 2012
)
0.38
"Results revealed that both the coating composition and the coating weight significantly affected the release of drug from the dosage form."( Design and optimization of a chronotherapeutic dosage form for treatment of nocturnal acid breakthrough.
Agarwal, V; Bansal, M, 2012
)
0.38
"This study evaluated the effects of either famotidine or antacid on the pharmacokinetics of nilotinib in healthy subjects, with the specific focus to explore different dosing separation schemes leading to a minimized drug-drug interaction."( Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.
Bédoucha, V; Hussaini, A; McCulloch, T; Novick, S; Yin, OQ; Zheng, C; Zhou, W, 2013
)
1.04
"Results revealed that both the coating composition and the coating weight significantly affected the release of drug from the dosage form."( Statistical optimization and fabrication of a press coated pulsatile dosage form to treat nocturnal acid breakthrough.
Agarwal, V; Bansal, M, 2013
)
0.39
" Greater potency of famotidine may offer clinical advantage due to lower drug exposure and less frequent dosing to achieve same pH lowering effect."( Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Kauffman, R; Lai, ML; Lehr, VT; Madani, S; Sarniak, A; Simpson, P; Tolia, V, 2014
)
0.99
" Lipids were utilized in the formulation of novel gastroretentive dosage forms to increase the availability of famotidine HCl at its absorption site."( Design and development of novel lipid based gastroretentive delivery system: response surface analysis, in-vivo imaging and pharmacokinetic study.
Ahmed Abdelbary, A; Elsayed, I; Hassen Elshafeey, A, 2015
)
0.63
" pylori-positive and 10-negative subjects) with 100 mg aspirin plus 75 mg clopidogrel (AC) once-daily dosing and AC plus 20 mg famotidine twice-daily dosing (ACH)."( Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2014
)
0.84
" NQR can also measure their ratio in a solid mixture and in the final dosage form, that is, a tablet."( ¹⁴N nuclear quadrupole resonance study of polymorphism in famotidine.
Jazbinšek, V; Lavrič, Z; Luźnik, J; Pirnat, J; Seliger, J; Srčič, S; Trontelj, Z; Žagar, V, 2014
)
0.65
"The objective of this study was to determine the impact of a pharmacy-managed pharmacokinetic dosing program on appropriate dosing of famotidine, enoxaparin, and ketorolac."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.62
"A large community teaching hospital implemented a pharmacy-managed pharmacokinetic dosing program for famotidine, enoxaparin, and ketorolac."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.63
" In all, 66% of patients were dosed appropriately in the preimplementation group (famotidine 28%, enoxaparin 85%, and ketorolac 86%) compared to 94% in the postimplementation group (famotidine 92%, enoxaparin 95%, and ketorolac 94%), P < ."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.64
"Implementation of a pharmacy-managed pharmacokinetic dosing program significantly improved appropriate dosing of famotidine, enoxaparin, and ketorolac."( Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
Crannage, AJ; Korobey, MJ; Meyenburg, LK; Murphy, JA, 2015
)
0.63
"The gastroretentive dosage form of famotidine was modified using tamarind seed powders to prolong the gastric retention time."( Hydrogel polysaccharides of tamarind and xanthan to formulate hydrodynamically balanced matrix tablets of famotidine.
Karimian, H; Moghadamtousi, SZ; Noordin, MI; Nyamathulla, S; Razavi, M, 2014
)
0.89
" The suggested method was validated according to ICH guidelines and successfully applied for the analysis of ibuprofen and famotidine in their pharmaceutical dosage forms without interference from any additives or excipients."( Application of the ratio difference spectrophotometry to the determination of ibuprofen and famotidine in their combined dosage form: comparison with previously published spectrophotometric methods.
Elzanfaly, ES; Salem, MY; Soudi, AT; Zaazaa, HE, 2015
)
0.84
" Both methods were validated according to the ICH guidelines and applied for the determination of the two drugs in pure powder and combined dosage form without interference from the excipients."( Development and validation of chromatographic methods for simultaneous determination of ibuprofen and famotidine in presence of related substances in pharmaceutical formulations.
Elzanfaly, ES; Salem, MY; Soudi, AT; Zaazaa, HE, 2015
)
0.63
"The aim of this work was to prepare a combined drug dosage form of famotidine (FAM) and quercetin (QRT) to augment treatment of gastric ulcer."( Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study.
Abourehab, MA; Ahmed, OA; Khaled, KA; Sarhan, HA, 2015
)
0.96
" Simulations showed good agreement with plasma levels measured after oral dosing in dogs."( Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
Crison, J; Fung, NK; Good, DJ; Haddadin, R; Hartley, R; Hussain, M; Koo, O; Mathias, N; Nikfar, F; Timmins, P; Tirucherai, G, 2015
)
0.42
" The proposed IPC method was successfully applied for the determination of pharmaceutical dosage forms without prior need for separation."( An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists.
Ahmed, S; Elshaboury, SR; Farrag, S; Mohamed, NA, 2016
)
0.43
" Compared with other H2RAs, famotidine had the best short-term therapeutic effect in adults with GERD, especially at a dosage of 80 mg per day."( Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Liu, L; Wang, S; Wang, Y; Zhao, F, 2016
)
0.73
" This study also showed that the histamine-2 receptor antagonist famotidine and local antacid with staggered dosing had no impact on palbociclib exposure under fed conditions."( Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Kirkovsky, L; Klamerus, KJ; Kosa, M; O'Gorman, M; Pawlak, S; Plotka, A; Sun, W; Wang, D; Yuhas, LM, 2017
)
0.69
" The developed method was simple, rapid and reliable hence it could be applied for routine quality control analysis of the investigated H2-receptor antagonists in dosage forms."( Development of a Validated Comparative Stability-Indicating Assay Method for Some H2-Receptor Antagonists.
Ahmed, S; Elshaboury, SR; Farrag, S; Mohamed, NA, 2017
)
0.46
" In case of tablet formulation, the role of binders is very important for solubility of dosage form as well as drug."( A New Approach to Enhance the Solubility of Famotidine Tablet by Using Naturally Isolated Pear Starch.
Anjali, K; Manjul, SP, 2018
)
0.74
" Our findings will contribute to the development of oral dosage forms of insulin for noncovalent strategies involving CPP."( Exploration of the Key Factors for Optimizing the in Vivo Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides.
Hasegawa, R; Kamei, N; Shigei, C; Takeda-Morishita, M, 2018
)
0.48
"Clinical data indicated considerable pH dependent absorption of the drug when dosed in the presence of H2-antagonists."( Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.
Buzescu, A; Crison, J; Gesenberg, C; Good, DJ; Hemenway, JN; Mathias, NR; Narang, AS; Patel, J; Saari, A; Savant, I; Schartman, RR; Xu, Y; Zheng, N, 2019
)
0.51
" It was deducted from the current study that the Eudragit RL 100 can be efficiently incorporated in the formulation of controlled release dosage forms with predictable kinetics."( Formulation and assessment of controlled release tablets of famotidine by using eudragit RL 100 polymer.
Ahmad Khan, K; Gul, R; Rabani, T; Rashid, F; Razaque, G; Tufail, M; Umer Jan, S, 2022
)
0.96
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
H2-receptor antagonistH2-receptor antagonists are the drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of endogenous histamine.
P450 inhibitorAn enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
H2-receptor antagonistH2-receptor antagonists are the drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of endogenous histamine.
P450 inhibitorAn enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
1,3-thiazoles
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
1,3-thiazoles
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Famotidine Action Pathway1012

Protein Targets (54)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency16.36000.001310.157742.8575AID1259252; AID1259253; AID1259256
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.51190.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency22.38720.631035.7641100.0000AID504339
Chain A, CruzipainTrypanosoma cruziPotency12.92440.002014.677939.8107AID1476; AID1478
phosphopantetheinyl transferaseBacillus subtilisPotency70.79460.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521
GLS proteinHomo sapiens (human)Potency3.54810.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686979
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency15.84890.707912.194339.8107AID720542
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
progesterone receptorHomo sapiens (human)Potency29.84930.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.71010.001530.607315,848.9004AID1224821
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.96010.000229.305416,493.5996AID743080
cytochrome P450 2D6Homo sapiens (human)Potency27.54040.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.43440.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00160.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency95.283423.934123.934123.9341AID1967
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency22.38720.354828.065989.1251AID504847
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency23.77810.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency10.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.58050.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.57970.005612.367736.1254AID624044
lamin isoform A-delta10Homo sapiens (human)Potency1.97780.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency2.10070.00339.158239.8107AID1347407
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency5.01191.000010.475628.1838AID1457
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)36.10000.40003.10009.7000AID721751
Solute carrier family 22 member 2Homo sapiens (human)Ki1,800.00000.10001.52203.4000AID680368
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)300.00000.21005.553710.0000AID721750
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Carbonic anhydrase 12Homo sapiens (human)Ki0.04530.00021.10439.9000AID1422971
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Solute carrier family 22 member 3Homo sapiens (human)IC50 (µMol)10.70000.09003.72779.5000AID721749
Bile salt export pumpHomo sapiens (human)IC50 (µMol)422.66670.11007.190310.0000AID1209455; AID1443980; AID1473738
Carbonic anhydrase 1Homo sapiens (human)Ki0.92240.00001.372610.0000AID1422962
Carbonic anhydrase 2Homo sapiens (human)Ki0.05790.00000.72369.9200AID1422963
Carbonic anhydrase 3Homo sapiens (human)Ki10.00000.00022.010210.0000AID1422964
Carbonic anhydrase 4Homo sapiens (human)Ki0.93880.00021.97209.9200AID1422965
Carbonic anhydrase 6Homo sapiens (human)Ki0.09820.00011.47109.9200AID1422968
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)0.04200.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki0.04100.00062.197310.0000AID625270
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki1.42950.00001.27259.9000AID1422966
Carbonic anhydrase 7Homo sapiens (human)Ki0.00300.00021.37379.9000AID1422969
Carbonic anhydrase 9Homo sapiens (human)Ki0.12630.00010.78749.9000AID1422970
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)36.20000.16003.95718.6000AID721752
Carbonic anhydrase 13Homo sapiens (human)Ki0.17150.00031.23099.8000AID1422972
Solute carrier family 22 member 8Homo sapiens (human)Ki300.00000.04004.22979.0000AID679677
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)0.76000.01002.765610.0000AID721754
Histamine H4 receptorHomo sapiens (human)Ki10.00000.00060.478710.0000AID1798265
Carbonic anhydrase 14Homo sapiens (human)Ki0.67720.00021.50999.9000AID1422973
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki5.32820.00001.34129.9700AID1422967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)Kd0.10000.01170.15720.9550AID88151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km35.70002.10005.39008.6000AID1769498
Solute carrier family 22 member 8Homo sapiens (human)Km124.00000.34501.32173.1000AID679305
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (150)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 13Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein bindingCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 13Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 13Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
myelin sheathCarbonic anhydrase 13Homo sapiens (human)
intracellular membrane-bounded organelleCarbonic anhydrase 13Homo sapiens (human)
cytoplasmCarbonic anhydrase 13Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (271)

Assay IDTitleYearJournalArticle
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID183686Inhibition of histamine stimulated gastric acid secretion in lumen perfused anaesthetized rats after 1 mg/kg intravenous dose1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID91435Inhibition against HIV-1 integrase at 1 mM2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID445447Clearance in human assessed as liver blood flow2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID91436Inhibition against HIV-1 integrase at 200 uM2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
AID1529185Protein binding in human serum albumin after 4.5 hrs by LC-MS based rapid equilibrium dialysis method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID183872In Vivo gastric Mucosal protective activity against gastric mucosal lesions induced by 0.6 N HCl in rats. (200 mg/kg, po)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID410192Inhibition of water-immersion stress-induced ulcer formation in rat at 3 mg/kg2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Possible involvement of radical intermediates in the inhibition of cysteine proteases by allenyl esters and amides.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID179018Effect on gastric mucosal blood flow 15 minutes before dosing of HCl and aspirin after drug dosing at 32 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID721741Selectivity ratio of IC50 for human OCT1-mediated ASP+ uptake expressed in HEK293 cells to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID179024Effect on gastric mucosal blood flow 60 minutes after administration of HCl and aspirin after drug dosing at 32 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1422963Inhibition of recombinant human CA2 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID1422966Inhibition of recombinant human CA5a preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID177854Effective dose against indomethacin induced gastric lesions in rats after peroral administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID181894In vivo gastric antisecretory activity in acute fistula rats (5 mg/kg, id)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.
AID1422975Inhibition of recombinant Helicobacter pylori beta carbonic anhydrase preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID540235Phospholipidosis-negative literature compound
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID59666Effective dose against tetragastrin stimulated gastric acid secretion in conscious Hiedenhain-pouch dogs after peroral administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID678841TP_TRANSPORTER: inhibition of PHA uptake (PHA: 1000uM) in mOat3-expressing oocytes2004Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID179020Effect on gastric mucosal blood flow 30 minutes after administration of HCl and aspirin after drug dosing at 10 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1864509Substrate uptake in empty vector transfected (OCT3 null) HEK293 cells incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID88156Histamine H2 receptor antagonistic activity on the isolated spontaneously beating guinea pig right atrium2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID680368TP_TRANSPORTER: inhibition of TEA uptake in OCT2 expressing oocytes2004European journal of pharmacology, Oct-25, Volume: 503, Issue:1-3
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1864500Substrate activity at human OCT1 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID681033TP_TRANSPORTER: uptake in OAT3 expressing oocyte2004European journal of pharmacology, Oct-25, Volume: 503, Issue:1-3
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1422970Inhibition of recombinant human CA9 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID1422962Inhibition of recombinant human CA1 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID179023Effect on gastric mucosal blood flow 60 minutes after administration of HCl and aspirin after drug dosing at 10 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1422964Inhibition of recombinant human CA3 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID87878Compound was tested for H2 receptor antagonistic activity against histamine stimulated chronotropic response in isolated guinea pig right atrium1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1864501Inhibition of human OCT3 mediated ASP+ uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864502Inhibition of human OCT3 mediated (S,S)-Ethambutol uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID721749Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1422967Inhibition of recombinant human CA5b preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1422968Inhibition of recombinant human CA6 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID721750Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID179027Effect on gastric mucosal blood flow at basal value which is 15 minutes before dosing of drugs at 32 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID177835Effective dose against aspirin induced gastric lesions in rats after peroral administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID721740Selectivity ratio of IC50 for human OCT2-mediated ASP+ uptake expressed in HEK293 cells to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1422973Inhibition of recombinant human CA14 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1422965Inhibition of recombinant human CA4 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID1422969Inhibition of recombinant human CA7 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID179026Effect on gastric mucosal blood flow at basal value which is 15 minutes before dosing of drugs at 10 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID679677TP_TRANSPORTER: inhibition of E1S uptake in OAT3 expressing oocytes2004European journal of pharmacology, Oct-25, Volume: 503, Issue:1-3
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID179021Effect on gastric mucosal blood flow 30 minutes after administration of HCl and aspirin after drug dosing at 32 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1422971Inhibition of recombinant human CA12 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID721739Selectivity ratio of IC50 for human OCT3-mediated ASP+ uptake expressed in HEK293 cells to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1864508Substrate uptake at human OCT3 overexpressed in HEK293 cells incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID87867Histamine H2 receptor antagonist activity (chronotropic response to histamine) in guinea pig right atrium1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives.
AID87882H2 receptor antagonistic activity against histamine stimulated chronotropic response in isolated guinea pig right atrium at 1x10E-6 g/mL.1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1864504Inhibition of human OCT3 mediated N-Ethyllidocaine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID179017Effect on gastric mucosal blood flow 15 minutes before dosing of HCl and aspirin after drug dosing at 10 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID88151In vitro inhibitory activity against histamine H2-receptor in isolated Guinea pig right atria.1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID183685Inhibition of aspirin induced gastric lesions in rats after peroral dose of 32 mg/kg1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID60224Evaluated against tetragastrin stimulated gastric acid secretion in conscious Hiedenhain-pouch dogs at a dose of 0.32 mg/kg, po1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID60029Reduction in gastric acid secretion under histamine[160 ug/(kg h)] stimulation in anesthetized dogs after intravenous administration1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives.
AID1864498Substrate activity at human OCT3 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1422972Inhibition of recombinant human CA13 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID176400Evaluated for inhibition of basal gastric acid secretion in pyolus-ligated rats after intravenous administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID679305TP_TRANSPORTER: cell accumulation in hOAT3 expressing HEK cells2006The Journal of pharmacology and experimental therapeutics, Mar, Volume: 316, Issue:3
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1864505Inhibition of human OCT3 mediated methylscopolamine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864499Substrate activity at human OCT2 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1422974Inhibition of recombinant Helicobacter pylori alpha carbonic anhydrase preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red based stopped-flow CO2 hydration assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Famotidine, an Antiulcer Agent, Strongly Inhibits
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1798265H4R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,624)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990275 (16.93)18.7374
1990's580 (35.71)18.2507
2000's381 (23.46)29.6817
2010's274 (16.87)24.3611
2020's114 (7.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 90.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index90.88 (24.57)
Research Supply Index7.70 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index251.68 (26.88)
Search Engine Supply Index3.01 (0.95)

This Compound (90.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials500 (29.36%)5.53%
Trials0 (0.00%)5.53%
Reviews90 (5.28%)6.00%
Reviews2 (3.17%)6.00%
Case Studies119 (6.99%)4.05%
Case Studies0 (0.00%)4.05%
Observational2 (0.12%)0.25%
Observational0 (0.00%)0.25%
Other992 (58.25%)84.16%
Other61 (96.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (102)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Open-label, Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants [NCT04470778]Phase 135 participants (Actual)Interventional2020-07-20Completed
Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series [NCT04389567]10 participants (Actual)Observational2020-05-12Completed
Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial [NCT01180179]Phase 4228 participants (Actual)Interventional2010-06-30Completed
A Phase 1, 2-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Itraconazole, Food, and pH, on the Single Dose Pharmacokinetics of BMS-986368 in Healthy Participants [NCT06170723]Phase 132 participants (Anticipated)Interventional2024-01-12Not yet recruiting
A Phase 1, Open-label, Crossover Study to Evaluate the Pharmacokinetics of Deucravacitinib (BMS-986165) Administered as Various Solid Tablet Formulations in Healthy Subjects [NCT04949269]Phase 161 participants (Actual)Interventional2021-07-20Completed
Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma. [NCT03647072]Phase 360 participants (Anticipated)Interventional2018-08-01Recruiting
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia [NCT03805932]Phase 118 participants (Actual)Interventional2019-10-03Active, not recruiting
[NCT01079052]24 participants (Actual)Interventional2007-11-30Completed
A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants [NCT05866627]Phase 176 participants (Anticipated)Interventional2023-07-04Recruiting
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prodrug BMS-986465 and Its Active Derivative, BMS-986464, in [NCT06144697]Phase 1132 participants (Anticipated)Interventional2024-01-17Not yet recruiting
The Use of Propofol/Ketamine Anesthesia With Bispectral Monitoring (PKA-BIS) Versus Inhalational Anesthetics in Rhytidoplasty - A Prospective, Double-blinded, Randomized Comparison Study [NCT02410460]30 participants (Actual)Interventional2013-09-30Completed
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric Cancer [NCT04308837]Phase 229 participants (Anticipated)Interventional2018-12-03Recruiting
A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III [NCT04990388]Phase 1/Phase 28 participants (Actual)Interventional2021-10-18Terminated(stopped due to Sponsor decision not related to safety concerns)
A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986322 in Healthy Participants Including an Open-label Assessment of Food and pH Effects on Relative Bioa [NCT04175925]Phase 1171 participants (Actual)Interventional2019-11-15Completed
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients [NCT04488081]Phase 21,500 participants (Anticipated)Interventional2020-07-31Recruiting
Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients. [NCT04504240]Phase 3208 participants (Actual)Interventional2020-08-01Completed
A Phase 1 Open-label, 2-Period Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants [NCT04941755]Phase 122 participants (Actual)Interventional2021-06-25Completed
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine With or Without Tenofovir on the Pharmacokinetics of Atazanavir When Given With Ritonavir in HIV-Infected Subjects [NCT00384904]Phase 440 participants (Actual)Interventional2006-12-31Completed
Proof-of-concept Randomized Placebo-controlled Trial of Famotidine for Outpatients With COVID-19 [NCT04565392]Phase 40 participants (Actual)Interventional2021-05-01Withdrawn(stopped due to lack of funding)
Intraoperative Electrical Stimulation of the Acupoint P6 to Prevent Post-Operative Nausea and Vomiting in Women Undergoing Breast Cancer Surgery [NCT02473042]188 participants (Actual)Interventional2016-02-29Active, not recruiting
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir [NCT01232127]Phase 425 participants (Actual)Interventional2011-02-28Completed
An Open-label 3×3 Cross-over Study to Compare Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of Single Doses of BMS-986165 in Healthy Volunteers [NCT04209699]Phase 118 participants (Actual)Interventional2019-12-27Completed
A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) [NCT02684799]Phase 148 participants (Actual)Interventional2016-01-31Completed
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia [NCT01946295]Phase 2/Phase 3140 participants (Anticipated)Interventional2014-03-31Recruiting
A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects [NCT04935112]Phase 115 participants (Actual)Interventional2021-07-07Completed
Interest of Famotidine in Reducing Endothelial Expression of P-selectin in Children With Sickle Cell Disease: Pilot Study, Single-center, Prospective, Non-comparative. [NCT05084521]Phase 2/Phase 330 participants (Anticipated)Interventional2022-01-12Recruiting
A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers [NCT02097329]Phase 127 participants (Actual)Interventional2014-04-30Completed
Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Cetirizine and Famotidine in Reducing the Duration of Symptoms in Patients With COVID-19: A Pilot Study [NCT04836806]Phase 40 participants (Actual)Interventional2021-08-31Withdrawn(stopped due to Study stopped due to issues with enrollment and lack of funding.)
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Famotidine 20 mg Tablets of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With PEPCID AC Tablets (Contain [NCT01079065]32 participants (Actual)Interventional2007-11-30Completed
Clinical Effects of Famotidine Use in Intensive Care Covid-19 Patients [NCT05122208]60 participants (Actual)Observational2020-03-20Completed
"Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery." [NCT02703896]Phase 41,920 participants (Actual)Interventional2012-01-31Completed
Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit [NCT00633035]Phase 460 participants (Actual)Interventional2007-09-30Completed
A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19 [NCT04724720]Phase 256 participants (Actual)Interventional2021-01-19Active, not recruiting
A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer [NCT00422097]Phase 140 participants (Actual)Interventional2007-01-31Completed
A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial [NCT03107182]Phase 276 participants (Actual)Interventional2017-06-27Active, not recruiting
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) [NCT04918147]Phase 275 participants (Anticipated)Interventional2021-10-13Recruiting
A Phase 1, Open-Label, Non-Randomized, Two-Part, Fixed-Sequence, Study to Evaluate the Effects of Acid Reducing Agents on the Pharmacokinetics of PC14586 in Healthy Volunteers [NCT06054464]Phase 150 participants (Anticipated)Interventional2023-09-19Recruiting
Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine [NCT00950339]Phase 463 participants (Actual)Interventional2009-08-31Completed
A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment [NCT00450216]Phase 3906 participants (Actual)Interventional2007-03-31Completed
Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery [NCT00839488]Phase 46 participants (Actual)Interventional2008-04-30Terminated(stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study)
An Open-Label, Randomised, Two Part, Two Treatment Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Famotidine [NCT04179071]Phase 116 participants (Actual)Interventional2019-12-13Completed
Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction [NCT00683111]Phase 4500 participants (Anticipated)Interventional2008-07-31Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT00802828]Phase 144 participants (Actual)Interventional2004-06-30Completed
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Administered as Various Solid Dispersion Tablet Formulations in Healthy Subjects [NCT04065932]Phase 133 participants (Actual)Interventional2019-08-22Completed
A Phase II, Randomized, Placebo-controlled Study Evaluating the Efficacy of Antihistamines in the Treatment of Eosinophilic Esophagitis (the ATEE Study) [NCT04248712]Phase 21 participants (Actual)Interventional2020-07-10Terminated(stopped due to low enrollment)
Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study [NCT00843063]Phase 4161 participants (Actual)Interventional2004-08-31Completed
Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA) [NCT01408186]Phase 3264 participants (Actual)Interventional2011-01-31Completed
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986202 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetic [NCT02763969]Phase 1357 participants (Actual)Interventional2016-05-18Completed
In Infants With Symptoms of Tracheomalacia or Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? A Randomized, Controlled Trial [NCT02700087]0 participants (Actual)Interventional2016-02-29Withdrawn
Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel İlaç San. ve Tic. A.Ş., İstanbul / Türkiye) Versu [NCT01910090]Phase 136 participants (Actual)Interventional2012-12-31Completed
An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease [NCT01937078]Phase 27 participants (Actual)Interventional2011-04-30Completed
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis [NCT02555852]4,238,504 participants (Actual)Observational2011-09-30Completed
Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study [NCT00978159]Phase 4128 participants (Anticipated)Interventional2009-09-30Recruiting
A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine 20 mg Film-Coated Tablets (FCT) Compared to Famotidine 20 mg Chewable Tablets (CT) Without Water and Famotidine 20 mg Chewable Tablets (CTw) With Water (Pro [NCT00945750]Phase 130 participants (Actual)Interventional2006-08-31Completed
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986165 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetic [NCT02534636]Phase 1140 participants (Actual)Interventional2015-10-31Completed
Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin [NCT01062516]Phase 4100 participants (Anticipated)Interventional2010-01-31Completed
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia [NCT04614974]Phase 1/Phase 265 participants (Actual)Interventional2020-11-18Active, not recruiting
A 3-Part, Open-label Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects [NCT03451110]Phase 150 participants (Actual)Interventional2018-02-05Completed
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia [NCT00565175]Phase 430 participants (Actual)Interventional2008-01-31Completed
Double-Blind, Randomized, 2-Way Crossover Evaluation of the Impact of a Histamine-H2 Receptor Antagonist (H2RA) on the Pharmacokinetics of Telaglenastat Administered to Healthy Adult Subjects [NCT04540965]Phase 122 participants (Actual)Interventional2020-09-22Completed
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - [NCT00229424]Phase 3325 participants Interventional2005-04-30Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions [NCT00803192]Phase 144 participants (Actual)Interventional2004-06-30Completed
Open-label, Randomized, 2-way Crossover Study to Compare the Bioavailability of Reddy Cheminor and Merck &Co, Pepcid Famotidine Tablets 40 mg Under Fasting Conditions. [NCT01511731]Phase 130 participants (Actual)Interventional1998-10-31Completed
A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT03330028]Phase 129 participants (Actual)Interventional2017-10-27Completed
A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients [NCT05077969]Phase 29 participants (Actual)Interventional2021-12-29Terminated(stopped due to Low recruitment)
An Open-Label, 3-Part, 2-Period Study to Examine the Effect of Omeprazole (Part 1), Famotidine (Part 2), and of an Acidic Beverage (Part 3) on the Single-Dose Pharmacokinetics of Entinostat in Healthy Adult Subjects [NCT02922933]Phase 166 participants (Actual)Interventional2016-10-25Completed
Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease [NCT03667703]Phase 470 participants (Actual)Interventional2019-03-10Completed
A Phase 2 Screening Study of Candidate Non-prescription Treatments for COVID-19: A Patient-driven, Randomized, Factorial Study Evaluating Patient-reported Outcomes (PROFACT-01) [NCT04621149]Phase 210 participants (Actual)Interventional2020-11-15Terminated(stopped due to Unable to recruit participants due to decline in COVID-19.)
YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease [NCT00141960]Phase 2/Phase 3480 participants Interventional2005-09-30Completed
A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults [NCT04370262]Phase 3233 participants (Actual)Interventional2020-04-07Completed
An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen [NCT01000818]Phase 118 participants (Actual)Interventional2008-06-30Completed
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer [NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
A Phase 1, Open-label, Crossover Study to Evaluate the Pharmacokinetics of BMS-986165 Administered as Various Prototypic Solid Tablet Formulations in Healthy Subjects [NCT04536961]Phase 156 participants (Actual)Interventional2020-09-10Completed
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors [NCT00451880]Phase 1180 participants (Anticipated)Interventional2007-02-28Completed
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor: A Prospective Randomized Controlled Trial [NCT06154226]Phase 4100 participants (Anticipated)Interventional2023-12-01Not yet recruiting
The Impact of Upper Gastrointestinal Dysmotility on Aspiration-associated Symptoms [NCT05455359]Phase 4120 participants (Anticipated)Interventional2022-07-18Not yet recruiting
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized Trial [NCT04862585]Phase 2/Phase 3100 participants (Anticipated)Interventional2021-10-07Recruiting
A Phase 2 Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19 [NCT05085574]Phase 20 participants (Actual)Interventional2023-02-07Withdrawn(stopped due to COVID environment, lack of site confidence to enroll subjects, sites not suited to study procedures, decline of potential inpatient subjects at site)
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients [NCT05077332]Phase 22,000 participants (Anticipated)Interventional2021-12-29Active, not recruiting
A Randomized, Double-blind, Three-fold Cross-over, Multi-center Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid (1000 mg Hydrotalcite), a Single Dose of Oral Famotidine 10 mg, and a Single Dose of Placebo in Patients With Acute He [NCT01928888]Phase 4559 participants (Actual)Interventional2003-05-31Completed
Single-center, Randomized, Open-label Study to Investigate the Effect of Single-dose Famotidine and Multiple-dose Efavirenz on the Pharmacokinetics of Daridorexant in Healthy Male Subjects [NCT04390334]Phase 124 participants (Actual)Interventional2020-05-13Completed
An Open-label Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics of AMG 510 in Healthy Subjects Under Fed Conditions [NCT05599828]Phase 114 participants (Actual)Interventional2020-07-17Completed
Effect of Histamine 2 Receptor Antagonist (H2RA) and Proton Pump Inhibitor (PPI) on the Positivity Rates and Clinical Outcomes of Coronavirus Disease-19 (COVID-19). [NCT04834752]400,000 participants (Anticipated)Observational2021-05-01Not yet recruiting
A PHASE 1, RANDOMIZED, CROSSOVER STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF ABROCITINIB ORAL SUSPENSION AND EFFECT OF AN ACID-REDUCING AGENT ON THE BIOAVAILABILITY OF ABROCITINIB COMMERCIAL TABLET AND TO ASSESS THE TASTE OF ABROCITINIB ORAL FORMULATION [NCT04903093]Phase 119 participants (Actual)Interventional2021-06-04Completed
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension [NCT03554291]Phase 280 participants (Actual)Interventional2019-05-01Completed
A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets (FACT) Compared to Famotidine/Antacid EZ Chew Tablet Without Water and Famotidine/Antacid EZ Chew Tablet With Water [NCT00944671]Phase 124 participants (Actual)Interventional2008-02-29Completed
A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Hea [NCT04550195]Phase 126 participants (Actual)Interventional2020-09-17Completed
Role of Histamine H1/H2 Receptors in the Health- and Performance-promoting Adaptations to High-intensity Interval Training [NCT04450134]20 participants (Actual)Interventional2019-10-02Completed
A Feasibility Assessment of a Decentralized Platform Adaptive Double-Blind, Randomized Controlled Trial Investigating Repurposed Drugs in the Treatment of Post-Acute Sequelae of Coronavirus-19 (PASC) [NCT05946551]Phase 336 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Famotidine on the Pharmacokinetics of Atazanavir/Ritonavir/Tenofovir in Healthy Subjects [NCT00365339]Phase 140 participants Interventional2006-04-30Completed
Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. [NCT02142712]Phase 23 participants (Actual)Interventional2014-12-31Completed
A Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants [NCT03142165]Phase 133 participants (Actual)Interventional2017-05-11Completed
A Randomized, Double-blind Clinical Trial Comparing Zegerid Capsule to Famotidine in Preventing Anastomotic (Marginal) Ulcers in Post Gastric Bypass Patients [NCT00557349]Phase 440 participants (Actual)Interventional2006-11-30Completed
A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection [NCT04545008]Phase 12 participants (Actual)Interventional2020-10-20Terminated(stopped due to Study was stopped due to poor accrual.)
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT05977998]Phase 230 participants (Anticipated)Interventional2023-09-08Recruiting
A Phase 1, Open-label, Randomized, 2-Way Crossover Study to Assess the Effects of Acid-Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of JNJ-64417184 in Healthy Adult Participants [NCT04453189]Phase 114 participants (Actual)Interventional2020-07-20Completed
Potential Therapeutic Outcome of Combined Antihistaminics Therapy in COVID 19 Patients [NCT05043350]Phase 2/Phase 3214 participants (Actual)Interventional2021-09-13Completed
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients [NCT01499368]Phase 3495 participants (Actual)Interventional2011-11-30Completed
Optimal Multimodal Pain Management Package Versus Regular Bottled Pain Formulation for Outpatient Use Following Microdiscectomies , Foraminotomies, and Spinal Decompressions: A Randomized Control Trial Comparing Two Strategies [NCT05965492]Phase 3100 participants (Anticipated)Interventional2024-02-01Not yet recruiting
A Phase 1, Open-label, Parallel Group, Drug-drug Pharmacokinetic Interaction Study to Evaluate the Effects of Multiple-dose Omeprazole and Famotidine on the Absorption of Single-dose Telotristat Ethyl in Healthy Male and Female Subjects [NCT03302845]Phase 132 participants (Actual)Interventional2017-09-21Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial [NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis [NCT01563185]Phase 412 participants (Actual)Interventional2012-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00422097 (16) [back to overview]Area Under the Curve in 1 Dosing Interval (AUC[TAU]) of Oral Ixabepilone at MTD in Fasted and Fed Participants in Crossover Cohorts
NCT00422097 (16) [back to overview]Time of Maximum Plasma Concentration (Tmax) of Oral Ixabepilone With and Without Famotidine in Crossover Cohorts
NCT00422097 (16) [back to overview]Time of Maximum Plasma Concentration (Tmax)of Oral Ixabepilone at MTD in Fasted and Fed Participants in Crossover Cohorts
NCT00422097 (16) [back to overview]Maximum Tolerated Dose (MTD) of Ixabepilone
NCT00422097 (16) [back to overview]Plasma Half-life (T-Half) of Ixabepilone
NCT00422097 (16) [back to overview]Area Under the Concentration-time Curve in 1 Dosing Interval (AUC[TAU])of Ixabepilone
NCT00422097 (16) [back to overview]Area Under the Curve in 1 Dosing Interval (AUC[TAU]) of Oral Ixabepilone With and Without Famotidine in Crossover Cohorts
NCT00422097 (16) [back to overview]Maximum Plasma Concentration (Cmax) of Ixabepilone
NCT00422097 (16) [back to overview]Maximum Plasma Concentration (Cmax) of Oral Ixabepilone at MTD in Fasted and Fed Participants in Crossover Cohorts
NCT00422097 (16) [back to overview]Maximum Plasma Concentration (Cmax) of Oral Ixabepilone With and Without Famotidine in Crossover Cohorts
NCT00422097 (16) [back to overview]Number of Participants With Abnormal (CTC Grade 3 or Greater) Serum Chemistry Levels
NCT00422097 (16) [back to overview]Number of Participants With Abnormal Laboratory Values by Worst CTC Grade
NCT00422097 (16) [back to overview]Number of Participants With Death as Outcome, Treatment-related Adverse Events (AEs), and AEs Leading to Discontinuation
NCT00422097 (16) [back to overview]Number of Participants With DLTs by Worst Common Terminology Criteria (CTC) Grade
NCT00422097 (16) [back to overview]Number of Participants With Significant Findings on Physical Examination or Electrocardiogram (ECG)
NCT00422097 (16) [back to overview]Time of Maximum Plasma Concentration (Tmax) of Ixabepilone
NCT00450216 (4) [back to overview]Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.
NCT00450216 (4) [back to overview]Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers
NCT00450216 (4) [back to overview]Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.
NCT00450216 (4) [back to overview]The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)
NCT00557349 (2) [back to overview]Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia.
NCT00557349 (2) [back to overview]Number of Participants With Upper Endoscopy Indicated Due to Complaints
NCT00944671 (4) [back to overview]Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With Water
NCT00944671 (4) [back to overview]Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew With Water and Famotidine/Antacid Tablet With Water
NCT00944671 (4) [back to overview]Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew With Water and Famotidine/Antacid Tablet With Water
NCT00944671 (4) [back to overview]Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With Water
NCT00945750 (4) [back to overview]Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine CT Without Water and Famotidine FCT With Water
NCT00945750 (4) [back to overview]Cmax of Famotidine Following Single Dose Administration of Famotidine CT With Water and Famotidine FCT With Water
NCT00945750 (4) [back to overview]AUC 0-∞ Following Single Dose Administration of Famotidine CT With Water and Famotidine FCT With Water
NCT00945750 (4) [back to overview]Area Under the Concentration-time Curve From 0 to Infinity (AUC 0-∞) Following Single Dose Administration of Famotidine CT Without Water and Famotidine FCT With Water
NCT01000818 (1) [back to overview]Plasma Area Under Curve (AUC 0-12 hr ) for Raltegravir
NCT01232127 (7) [back to overview]Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest
NCT01232127 (7) [back to overview]Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir
NCT01232127 (7) [back to overview]Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings
NCT01232127 (7) [back to overview]Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir
NCT01232127 (7) [back to overview]Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir
NCT01232127 (7) [back to overview]Number of Participants With Abnormalities in Laboratory Test Results
NCT01232127 (7) [back to overview]Number of Participants With Abnormalities in Vital Signs
NCT01499368 (3) [back to overview]The Proportion of Days Without 'Cardinal Symptom'
NCT01499368 (3) [back to overview]The Proportion of Daytimes Without 'Cardinal Symptom'
NCT01499368 (3) [back to overview]The Proportion of Nighttimes Without 'Cardinal Symptom'
NCT01563185 (11) [back to overview]ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis
NCT01563185 (11) [back to overview]American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index
NCT01563185 (11) [back to overview]American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration
NCT01563185 (11) [back to overview]Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)
NCT01563185 (11) [back to overview]American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being
NCT01563185 (11) [back to overview]Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores
NCT01563185 (11) [back to overview]Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)
NCT01563185 (11) [back to overview]Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)
NCT01563185 (11) [back to overview]Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
NCT01563185 (11) [back to overview]Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))
NCT01563185 (11) [back to overview]Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)
NCT02142712 (2) [back to overview]Glasgow Coma Scale (GCS)
NCT02142712 (2) [back to overview]National Institutes of Health Stroke Severity (NIHSS) Scale
NCT02418312 (1) [back to overview]Number of Participants With Healed Peptic Ulcer
NCT02551744 (1) [back to overview]Number of Participants With Ulcer Recurrence
NCT03805932 (6) [back to overview]Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03805932 (6) [back to overview]Number of Participants With a Dose-limiting Toxicity (DLT)
NCT03805932 (6) [back to overview]Number of Participants Whose Cancer Shrinks or Disappears After Treatment
NCT03805932 (6) [back to overview]Number of Participants Who Are Minimal Residual Disease (MRD)-Free
NCT03805932 (6) [back to overview]Recommended Safe Dose of Rituximab/Ruxience
NCT03805932 (6) [back to overview]Recommended Safe Dose of Moxetumomab Pasudotox-tdfk
NCT04248712 (2) [back to overview]Adverse Events
NCT04248712 (2) [back to overview]Change in Maximum Eosinophil Count
NCT04545008 (3) [back to overview]Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0
NCT04545008 (3) [back to overview]Time to Symptom Resolution
NCT04545008 (3) [back to overview]Rate of Hospitalization

Area Under the Curve in 1 Dosing Interval (AUC[TAU]) of Oral Ixabepilone at MTD in Fasted and Fed Participants in Crossover Cohorts

After the ixabepilone MTD (25 mg) has been defined, participants who completed Cycle 1 (ixabepilone, 25 mg, given once daily orally on Days 1 through 5 of 21-day cycle, with participants fasting at least 4 hours before and 4 hours after treatment on all dosing days) then cross over to Cycle 2, during which they consume a standard lowfat meal starting 30 minutes prior to ixabepilone, 25 mg, administration on Day 1 of Cycle 2 only. Meal is consumed within a 30-minute period. Administration of the total oral dose should not exceed more than 10 minutes from start to finish. (NCT00422097)
Timeframe: Up to 24 hours postdose Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (21 days)

Interventionng*h/mL (Mean)
Fasted (Cycle 1)Fed (Cycle 2)
Ixabepilone, 25 mg/d190.22243.46

[back to top]

Time of Maximum Plasma Concentration (Tmax) of Oral Ixabepilone With and Without Famotidine in Crossover Cohorts

After the ixabepilone MTD (25 mg) has been defined, participants who completed Cycle 1 (ixabepilone, 25 mg, given once daily orally on Days 1 through 5 of 21-day cycle, with participants fasting at least 4 hours before and 4 hours after treatment on all dosing days) then cross over to Cycle 2, during which they receive famotidine, 40 mg. Prior to dosing on Day 1 of Cycle 2, famotidine administered in an oral dose 2 hours before ixabepilone 25-mg dose. (NCT00422097)
Timeframe: Up to 24 hours postdose Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (21 days)

Interventionng/mL (Median)
Without Famotidine (Cycle 1)With Famotidine (Cycle 2)
Ixabepilone, 25 mg/d3.04.0

[back to top]

Time of Maximum Plasma Concentration (Tmax)of Oral Ixabepilone at MTD in Fasted and Fed Participants in Crossover Cohorts

After the ixabepilone MTD (25 mg) has been defined, participants who completed Cycle 1 (ixabepilone, 25 mg, given once daily orally on Days 1 through 5 of 21-day cycle, with participants fasting at least 4 hours before and 4 hours after treatment on all dosing days) then cross over to Cycle 2, during which they consume a standard lowfat meal starting 30 minutes prior to ixabepilone, 25 mg, administration on Day 1 of Cycle 2 only. Meal is consumed within a 30-minute period. Administration of the total oral dose should not exceed more than 10 minutes from start to finish. (NCT00422097)
Timeframe: Up to 24 hours postdose Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (21 days)

Interventionng/mL (Median)
Fasted (Cycle 1)Fed (Cycle 2)
Ixabepilone, 25 mg/d2.04.0

[back to top]

Maximum Tolerated Dose (MTD) of Ixabepilone

MTD is based on Cycle 1 data only and defined as the maximum dose that can be administered to 6 participants with no more than 1 experiencing a dose-limiting toxicity (DLT) (or fewer than one third of participants if more than 6 receive treatment) with at least 2 participants experiencing a DLT at the next higher dose level. DLT=an event, such as neutropenia; thrombocytopenia; Gr 3 or 4 nausea or diarrhea; Gr 3 fatigue or asthenia; transient arthralgia or recalcitrant myalgia; and prolonged recovery from a toxicity, that occurs during the first course of treatment. (NCT00422097)
Timeframe: Days 1 through 21 (Cycle 1)

Interventionmg/d (Number)
All Treated Participants25

[back to top]

Plasma Half-life (T-Half) of Ixabepilone

(NCT00422097)
Timeframe: Day 5 of Cycle 1

InterventionHours (Mean)
Ixabepilone, 5 mg/d18.56
Ixabepilone, 10 mg/d47.00
Ixabepilone, 15 mg/d24.32
Ixabepilone, 20 mg/d35.25
Ixabepilone, 25 mg/d35.62
Ixabepilone, 30 mg/d34.14

[back to top]

Area Under the Concentration-time Curve in 1 Dosing Interval (AUC[TAU])of Ixabepilone

(NCT00422097)
Timeframe: Days 1 and 5 of Cycle 1

,,,,,
Interventionng*h/mL (Mean)
Day 1 (n=3, n=6, n=3, n=3, n=23, n=6)Day 5 (n=2, n=6, n=3, n=3, n=22, n=6)
Ixabepilone, 10 mg/d91.79143.85
Ixabepilone, 15 mg/d120.58179.82
Ixabepilone, 20 mg/d120.82222.73
Ixabepilone, 25 mg/d195.96348.07
Ixabepilone, 30 mg/d252.01545.42
Ixabepilone, 5 mg/d28.4021.83

[back to top]

Area Under the Curve in 1 Dosing Interval (AUC[TAU]) of Oral Ixabepilone With and Without Famotidine in Crossover Cohorts

After the ixabepilone MTD (25 mg) has been defined, participants who completed Cycle 1 (ixabepilone, 25 mg, given alone once daily orally on Days 1 through 5 of 21-day cycle, with participants fasting at least 4 hours before and 4 hours after treatment on all dosing days) then cross over to Cycle 2, during which they receive famotidine, 40 mg. Prior to dosing on Day 1 of Cycle 2, famotidine administered in an oral dose 2 hours before ixabepilone 25-mg dose. (NCT00422097)
Timeframe: Up to 24 hours postdose Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (21 days)

Interventionng*h/mL (Mean)
Without Famotidine (Cycle 1)With Famotidine (Cycle 2)
Ixabepilone, 25 mg/d218.36276.30

[back to top]

Maximum Plasma Concentration (Cmax) of Ixabepilone

(NCT00422097)
Timeframe: Days 1 and 5 of Cycle 1

,,,,,
Interventionng/mL (Mean)
Day1 (n=3, n=6, n=3, n=3, n=23, n=6)Day 5 (n=2, n=6, n=3, n=3, n=22, n=6)
Ixabepilone, 10 mg/d25.9320.34
Ixabepilone, 15 mg/d16.0422.17
Ixabepilone, 20 mg/d24.1032.73
Ixabepilone, 25 mg/d36.1457.99
Ixabepilone, 30 mg/d43.6766.48
Ixabepilone, 5 mg/d4.022.45

[back to top]

Maximum Plasma Concentration (Cmax) of Oral Ixabepilone at MTD in Fasted and Fed Participants in Crossover Cohorts

After the MTD has been defined, participants who completed Cycle 1 (ixabepilone, 25 mg, given once daily orally on Days 1 through 5 of 21-day cycle, with participants fasting at least 4 hours before and 4 hours after treatment on all dosing days) then cross over to Cycle 2, during which they consume a standard lowfat meal starting 30 minutes prior to ixabepilone, 25 mg, administration on Day 1 of Cycle 2 only. Meal is consumed within a 30-minute period. Administration of the total oral dose should not exceed more than 10 minutes from start to finish. (NCT00422097)
Timeframe: Up to 24 hours postdose Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (21 days)

Interventionng/mL (Mean)
Fasted (Cycle 1)Fed (Cycle 2)
Ixabepilone, 25 mg/d38.1144.76

[back to top]

Maximum Plasma Concentration (Cmax) of Oral Ixabepilone With and Without Famotidine in Crossover Cohorts

After the ixabepilone MTD (25 mg) has been defined, participants who completed Cycle 1 (ixabepilone, 25 mg, given once daily orally on Days 1 through 5 of 21-day cycle, with participants fasting at least 4 hours before and 4 hours after treatment on all dosing days) then cross over to Cycle 2, during which they receive famotidine, 40 mg. Prior to dosing on Day 1 of Cycle 2, famotidine administered in an oral dose 2 hours before ixabepilone 25-mg dose. (NCT00422097)
Timeframe: Up to 24 hours postdose Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (21 days)

Interventionng/mL (Mean)
Without Famotidine (Cycle 1)With Famotidine (Cycle 2)
Ixabepilone, 25 mg/d36.9166.16

[back to top]

Number of Participants With Abnormal (CTC Grade 3 or Greater) Serum Chemistry Levels

Upper limit of normal (ULN)=upper level of normal among all laboratory ranges. Alkaline phosphatase(U/L): Gr 3: >5.0-20.0*ULN; Gr 4: >20.0*ULN. Sodium (mEq/L): Gr 3: 120-<130 or >155-160; Gr 4 <120. Potassium (mEq/L): Gr 3: 2.5-<3.0 or >6.0-7.0; Gr 4: <2.5 or >7.0. Calcium (mg/dL): Gr 3: 6.0-<7.0 or >12.5-13.5; Gr 4: <6.0 or >13.5. Inorganic phosphorus (mg/dL): Gr 3: 1.0-<2.0; Gr 4: <1.0. Albumin (g/dL): Gr 3: <2.0. (NCT00422097)
Timeframe: At screening and predose Day 1, Cycle 1 (21 days)

InterventionParticipants (Number)
Low sodium (Grade 3)High sodium (Grade 3)Low albumin (Grade 3)Low alkaline phosphatase (Grade 3)Low potassium (Grade 3)Low potassium (Grade 4)Low total calcium (Grade 4)Low inorganic phosphorus (Grade 4)
All Treated Participants41311111

[back to top]

Number of Participants With Abnormal Laboratory Values by Worst CTC Grade

Lower limit of normal (LLN)=lowest level of normal among all laboratory ranges. Hemoglobin (g/dL): Gr 1: 10.0-NCT00422097)
Timeframe: Baseline and Days 1, 8, and 15 of Cycle 1 (21 days)

InterventionParticipants (Number)
Hemoglobin (Grade 1)Hemoglobin (Grade 2)Hemoglobin (Grade 3)Hemoglobin (Grade 4)Leukocytes (Grade 1)Leukocytes (Grade 2)Leukocytes (Grade 3)Leukocytes (Grade 4)Lymphocytes (Absolute) (Grade 1)Lymphocytes (Absolute) (Grade 2)Lymphocytes (Absolute) (Grade 3)Lymphocytes (Absolute) (Grade 4)Neutrophils (Absolute) (Grade 1)Neutrophils (Absolute) (Grade 2)Neutrophils (Absolute) (Grade 3)Neutrophils (Absolute) (Grade 4)Neutrophils + Bands (Absolute) (Grade 1)Neutrophils + Bands (Absolute) (Grade 2)Neutrophils + Bands (Absolute) (Grade 3)Neutrophils + Bands (Absolute) (Grade 4)Platelet Count (Grade 1)Platelet Count (Grade 2)Platelet Count (Grade 3)Platelet Count (Grade 4)
All Treated Participants19155074231414123301430143311

[back to top] [back to top]

Number of Participants With DLTs by Worst Common Terminology Criteria (CTC) Grade

Adverse events (AEs) graded by CTC version 3. Grade (Gr) 1=mild; Gr 2=moderate; Gr 3=severe; Gr 4=life threatening; Gr 5=Death related to AE. DLT is defined as an event related to ixabepilone that occurs during the first course of treatment. Includes neutropenia; thrombocytopenia; Gr 3 or 4 nausea, vomiting, or diarrhea despite adequate medical intervention and prophylaxis; Gr 3 fatigue or asthenia; transient arthralgia or myalgia unresponsive to medical intervention; any Gr 3 nonhematologic toxicity; and prolonged recovery from a toxicity. (NCT00422097)
Timeframe: Days 1 through 21 (Cycle 1), continuously

,,,,,
InterventionParticipants (Number)
Clostridium difficile colitis (Grade 3)Ileus (Grade 3)Abdominal pain (Grade 3)Fatigue (Grade 3)Neutropenic fever (Grade 3)Neutropenic fever (Grade 4)Dehydration (Grade 3)Diarrhea (Grade 3)Hypokalemia (Grade 3)Nausea (Grade 3)Vomiting (Grade 3)Mucosal inflammation (Grade 3)Neutropenia (Grade 4)Hypokalemia (Grade 4)Hypophosphatemia (Grade 4)Thrombocytopenia (Grade 4)Sudden death (Grade 5)
Ixabepilone, 10 mg/d11000000000000000
Ixabepilone, 15 mg/d00000000000000000
Ixabepilone, 20 mg/d00000000000000000
Ixabepilone, 25 mg/d00000000000011000
Ixabepilone, 30 mg/d01111212111110111
Ixabepilone, 5 mg/d00000000000000000

[back to top]

Number of Participants With Significant Findings on Physical Examination or Electrocardiogram (ECG)

Physical examination evaluated height, weight, Eastern Cooperative Oncology Group performance status, adverse events, and abnormal laboratory findings and included a neurologic examination to evaluate deep tendon reflexes, sensory modalities, and motor strength. Participants also underwent a 12-lead ECG screening. Physical examination findings and ECG findings were considered clinically significant at the investigator's discretion. (NCT00422097)
Timeframe: At screening and predose Day 1, Cycle 1 (21 days)

,,,,,
InterventionParticipants (Number)
With abnormal physical examination findingsWith abnormal ECG results
Ixabepilone, 10 mg/d00
Ixabepilone, 15 mg/d00
Ixabepilone, 20 mg/d00
Ixabepilone, 25 mg/d00
Ixabepilone, 30 mg/d00
Ixabepilone, 5 mg/d00

[back to top]

Time of Maximum Plasma Concentration (Tmax) of Ixabepilone

(NCT00422097)
Timeframe: Days 1 and 5 of Cycle 1

,,,,,
InterventionHour (Median)
Day1 (n=3, n=6, n=3, n=3, n=23, n=6)Day 5 (n=2, n=6, n=3, n=3, n=22, n=6)
Ixabepilone, 10 mg/d1.82.5
Ixabepilone, 15 mg/d4.05.0
Ixabepilone, 20 mg/d2.01.5
Ixabepilone, 25 mg/d2.01.8
Ixabepilone, 30 mg/d3.03.5
Ixabepilone, 5 mg/d2.02.3

[back to top]

Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-5018
Ibuprofen14

[back to top]

Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers

The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-50155
Ibuprofen52

[back to top]

Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks

Interventionparticipants (Number)
HZT-50163
Ibuprofen61

[back to top]

The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)

The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks

Interventionparticpants (Number)
HZT-5013
Ibuprofen0

[back to top]

Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia.

(NCT00557349)
Timeframe: during first 14 weeks after surgery

Interventionparticipants (Number)
Omeprazole17
Famotidine13

[back to top]

Number of Participants With Upper Endoscopy Indicated Due to Complaints

Endoscopic visualization of presence or absence of anastomotic ulcers if upper endoscopy indicated due to patient complaints - based upon severity of complaints (NCT00557349)
Timeframe: during first 14 weeks after surgery

Interventionparticipants (Number)
Omeprazole1
Famotidine13

[back to top]

Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With Water

(NCT00944671)
Timeframe: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Interventionng*hr/mL (Geometric Mean)
Famotidine/Antacid Combination EZ Chew Tablet Without Water261.2
Famotidine/Antacid Combination Tablet With Water248.0

[back to top]

Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew With Water and Famotidine/Antacid Tablet With Water

(NCT00944671)
Timeframe: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Interventionng*h/mL (Geometric Mean)
Famotidine/Antacid Combination EZ Chew Tablet With Water260.1
Famotidine/Antacid Combination Tablet With Water248.0

[back to top]

Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew With Water and Famotidine/Antacid Tablet With Water

(NCT00944671)
Timeframe: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Interventionng/mL (Geometric Mean)
Famotidine/Antacid Combination EZ Chew Tablet With Water45.9
Famotidine/Antacid Combination Tablet With Water44.4

[back to top]

Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With Water

(NCT00944671)
Timeframe: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Interventionng/mL (Geometric Mean)
Famotidine/Antacid Combination EZ Chew Tablet Without Water45.5
Famotidine/Antacid Combination Tablet With Water44.4

[back to top]

Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine CT Without Water and Famotidine FCT With Water

Cmax values were natural log-transformed and analyzed using an ANOVA model. The ANOVA model contained factors for participant (random effect), period, treatment, and within-participant error. (NCT00945750)
Timeframe: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose

Interventionng/mL (Geometric Mean)
Famotidine 20 mg CT Without Water67.2
Famotidine 20 mg FCT With Water65.1

[back to top]

Cmax of Famotidine Following Single Dose Administration of Famotidine CT With Water and Famotidine FCT With Water

Cmax values were natural log-transformed and analyzed using an ANOVA model. The ANOVA model contained factors for participant (random effect), period, treatment, and within-participant error. (NCT00945750)
Timeframe: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose

Interventionng/mL (Geometric Mean)
Famotidine 20 mg CT With Water73.0
Famotidine 20 mg FCT With Water65.1

[back to top]

AUC 0-∞ Following Single Dose Administration of Famotidine CT With Water and Famotidine FCT With Water

AUC values were natural log-transformed and analyzed using an ANOVA model. The ANOVA model contained factors for participant (random effect), period, treatment, and within-participant error. (NCT00945750)
Timeframe: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose

Interventionng/mL hr (Geometric Mean)
Famotidine 20 mg CT With Water440.1
Famotidine 20 mg FCT With Water394.8

[back to top]

Area Under the Concentration-time Curve From 0 to Infinity (AUC 0-∞) Following Single Dose Administration of Famotidine CT Without Water and Famotidine FCT With Water

AUC values were natural log-transformed and analyzed using an analysis of variance (ANOVA) model. The ANOVA model contained factors for participant (random effect), period, treatment, and within-participant error. (NCT00945750)
Timeframe: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose

Interventionng/mL hr (Geometric Mean)
Famotidine 20 mg CT Without Water398.5
Famotidine 20 mg FCT With Water394.8

[back to top]

Plasma Area Under Curve (AUC 0-12 hr ) for Raltegravir

Area Under the Plasma Concentration-Time Curve and peak concentration (NCT01000818)
Timeframe: 12 hours postdose

InterventionµM*hr (Geometric Mean)
400 mg Raltegravir12.36
20 mg Famotidine + 400 mg Raltegravir17.95
20 mg Omeprazole + 400 mg Raltegravir17.12

[back to top]

Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT01232127)
Timeframe: Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.

,,
InterventionParticipants (Number)
DeathsSAEsAEs leading to discontinuationAEsAEs of clinical interest: NauseaAEs of clinical interest: Diarrhea
Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI000600
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)000723
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)000500

[back to top]

Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir

(NCT01232127)
Timeframe: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

,,
InterventionHours (Median)
Atazanavir TmaxRitonavir Tmax
Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI3.04.0
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)3.04.00
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)3.04.0

[back to top]

Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings

ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities. (NCT01232127)
Timeframe: Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.

InterventionParticipants (Number)
Nonspecific ST/T wave abnormalityShort PR interval
All Treated11

[back to top]

Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir

(NCT01232127)
Timeframe: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

,,
Interventionng*h/mL (Geometric Mean)
Atazanavir AUCRitonavir AUC
Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI325627317
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)378947430
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)314817052

[back to top]

Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir

(NCT01232127)
Timeframe: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

,,
Interventionng/mL (Geometric Mean)
Atazanavir CmaxAtazanavir CtroughRitonavir CmaxRitonavir Ctrough
Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI3512496114145.8
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)4131602114849.2
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)3322494109647.3

[back to top]

Number of Participants With Abnormalities in Laboratory Test Results

PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10*3 c/uL): <0.85*PreRx, if PreRx <1.5; <1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): >1.25*PreRx if PreRx >ULN; >1.25*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: >1.1*ULN if PreRx ≤ULN;> 1.1*ULN if PreRx is missing; >1.25*PreRx if PreRx >ULN. Bilirubin, total (mg/dL), high: >1.1*ULN if PreRx ≤ULN;> 1.1*ULN if PreRx is missing; >1.25*PreRx if PreRx >ULN. (NCT01232127)
Timeframe: Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.

,,
InterventionParticipants (Number)
WBC differential count (low)Neutrophils (absolute) (low)Alanine aminotransferase (high)Aspartate aminotransferase (high)Bilirubin, direct (high)Bilirubin, total (high)
Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI100013
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)011007
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)000105

[back to top]

Number of Participants With Abnormalities in Vital Signs

Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate. (NCT01232127)
Timeframe: Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.

InterventionParticipants (Number)
Isolated decrease in heart rateSporadic respiration rate >16 bpm
All Treated211

[back to top]

The Proportion of Days Without 'Cardinal Symptom'

The proportion of days without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sesation in the chest, Acid reflux, Heartburn including chest pain (NCT01499368)
Timeframe: 4 or 8 week

,,
Interventionproportion of days (Mean)
week 4week 8week 8(LOCF)
Famotidine0.560.670.67
Lafutidine0.640.770.77
Omeprazole0.690.820.82

[back to top]

The Proportion of Daytimes Without 'Cardinal Symptom'

The proportion of daytimes without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain (NCT01499368)
Timeframe: 4 or 8 week

,,
Interventionproportion of days (Mean)
week 4week 8week 8(LOCF)
Famotidine0.680.760.76
Lafutidine0.740.830.83
Omeprazole0.770.870.87

[back to top]

The Proportion of Nighttimes Without 'Cardinal Symptom'

The proportion of Nighttimes without 'Cardinal symptom' after 4 or 8 treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain (NCT01499368)
Timeframe: 4 or 8 week

,,
Interventionproportion of days (Mean)
week 4week 8week 8(LOCF)
Famotidine0.720.780.78
Lafutidine0.750.870.87
Omeprazole0.820.890.89

[back to top]

ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis

"The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: number of joints with active arthritis and the number of joints with limited range of motion. These ACR values represent the average change in number of joints with active arthritis and the number of joints with limited range of motion from the baseline visit to the week 24/ET visit.~The joints that were assessed include the right and left temporomandibular, sternoclavicular, arcomiclavicular, shoulder, elbow, wrist, MCP - 1. MCP - 2, MCP - 3, MCP - 4, MCP - 5, PIP - 1, PIP - 2, PIP - 3, PIP - 4, PIP - 5, DIP - 1, DIP - 2, DIP - 3, DIP - 4, and DIP - 5." (NCT01563185)
Timeframe: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

InterventionNumber of joints (Mean)
Number of joints with active arthritisNumber of joints with limited range of motion
DUEXIS-4.3-1.7

[back to top]

American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index

The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CHAQ - Disability Index. This ACR measurement represents the average change in the Childhood Health Assessment Questionnaire (CHAQ) - Disability Index from the baseline visit to the week 24/ET visit. The CHAQ disability index is measured on a scale of 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do). (NCT01563185)
Timeframe: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

Interventionunits on a scale (Mean)
DUEXIS-0.146

[back to top]

American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration

The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CRP Concentration. This ACR value represents the average change in Serum C Reactive Protein (CRP) Concentration from the baseline visit to the week 24/ET visit. The normal range referenced was 0 mg/L - 4.99 mg/L. (NCT01563185)
Timeframe: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

Interventionmg/L (Mean)
DUEXIS1.019

[back to top]

Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)

Tmax was estimated for ibuprofen and famotidine.The PK parameters for ibuprofen and famotidine represent average Tmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration. (NCT01563185)
Timeframe: Pre-dose, 0.5, 1, 2, 4, 8 hours post-dose

Interventionhours (Mean)
Tmax: IbuprofenTmax: Famotidine
DUEXIS1.752.1

[back to top]

American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being

The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: the physician's global assessment of disease activity and the parent's global assessment of overall well-being. These ACR values represent the average change in the physician's global assessment of disease activity and the parent's global assessment of overall well-being from the baseline visit to the week 24/ET visit. The ACR pediatric core measure: Physician's global assessment of disease activity and parent's assessment of overall well being was measured on a scale of 0-100 mm (0 = very good, 100=very poor). (NCT01563185)
Timeframe: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

Interventionunits on a scale (Mean)
Physician's Global Assessment of Disease ActivityParent's Global Assessment of Overall Well-Being
DUEXIS-9.1-8.0

[back to top]

Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores

"To assess patient quality of life while on study medication, the CHQ was administered to the patients' parent or guardian on Day 0 and at the Week 24/ET visit. The raw scale scores were transformed into scores on a 0 to 100 scale, 100 indicating best health and 0 indicating worst health. The algorithm is:~Transformed Score = ((Actual Raw Score - Lowest Possible Raw Score)/(Possible Raw Score Range)) x100. The actual raw score is the mean of the item responses in a scale (sum of item responses/number of completed items). The possible raw score range is the highest possible raw score minus the lowest possible raw score. The outcome measure data table shows the average change in the CHQ concepts from Baseline to the week 24 visit. The average change in the CHQ concepts is on a -100 to 100 scale, -100 representing a negative change in health and 100 indicating a positive change in health." (NCT01563185)
Timeframe: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

Interventionunits on a scale (Mean)
Global HealthPhysical FunctioningRole/Social Limitations: Emotional/BehavioralRole/Social Limitations: PhysicalBodily Pain/DiscomfortBehaviorGlobal Behavior ItemMental HealthSelf EsteemGeneral Health PerceptionsChange in HealthParental Impact: EmotionalParental Impact:TimeFamily ActivitiesFamily Cohesion
DUEXIS2.519.014.820.815.88.46.73.35.31.914.620.422.214.34.6

[back to top]

Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)

CL/F was estimated in ibuprofen and famotidine. (NCT01563185)
Timeframe: Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group

InterventionL/h/70 kg (Mean)
CL/F: IbuprofenCL/F: Famotidine
DUEXIS2.861.5

[back to top]

Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)

V/F were estimated in ibuprofen and famotidine. (NCT01563185)
Timeframe: Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group

InterventionL/70 kg (Mean)
V/F: IbuprofenV/F: Famotidine
DUEXIS16.7564.4

[back to top]

Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)

Safety assessments included AE monitoring, concomitant medication review, physical examinations (including vital signs and weight), and clinical laboratory assessments, including pregnancy testing for female patients. The outcome measure data table below describes the TEAEs experienced by patients. (NCT01563185)
Timeframe: Day 0 through Week 26/ET (adverse event data was collected at every visit, including telephone visits)

Interventionparticipants (Number)
Any patient with at least 1 TEAEAny patient with at least 1 mild TEAEAt least 1 moderate TEAEAt least 1 severe TEAEA possibly related TEAESAEA TEAE leading to study drug discontinuationA TEAE leading to deathTEAE: Gastrointestinal DisordersTEAE: General disordersTEAE: Infections and infestationsTEAE: Injury, poisoning & procedural complicationsTEAE: Muscoskeletal & connective tissue disordersTEAE: Nervous system disordersTEAE:Respiratory, thoracic & mediastinal disordersTEAE: Skin and subcutaneous tissue disorders
DUEXIS12750200042722132

[back to top]

Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))

AUC(0-t) was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average AUC values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration. (NCT01563185)
Timeframe: Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose

Interventionug*h/mL (Mean)
AUC(0-t): IbuprofenAUC(0-t): Famotidine
DUEXIS196.5267.6

[back to top]

Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)

Cmax was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average Cmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration. (NCT01563185)
Timeframe: Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose

Interventionug/mL (Mean)
Cmax: IbuprofenCmax: Famotidine
DUEXIS49.855.0

[back to top]

Glasgow Coma Scale (GCS)

Glasgow Coma Scale (GCS) is assessed by physical neurological examination of the subject by a qualified neurologist. GSC is a common scoring system used to describe the level of consciousness in a person following a traumatic brain injury. The initial score correlates with the severity of brain injury and prognosis. It estimates Coma severity based on Eye (4), Verbal (5), and Motor (6) criteria with the following total score of between 3 (indicating deep unconsciousness) and 15 (indicating no issues). (NCT02142712)
Timeframe: Baseline

InterventionGlasgow Coma Scale (Number)
Famotidine15
Pantoprazole15
Diphenhydramine15

[back to top]

National Institutes of Health Stroke Severity (NIHSS) Scale

NIHSS is a tool used by healthcare providers to objectively quantify the degree of impairment caused by a stroke. It is composed of 11 items. Each item scores a specific ability between a score of 0-4. Usually, for each item, a score of 0 indicates normal function in that specific ability, while a higher score indicates some level of impairment. The individual scores from each item are added together to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. (NCT02142712)
Timeframe: Baseline

InterventionNIHSS scale (Number)
Famotidine3
Pantoprazole3
Diphenhydramine0

[back to top]

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

[back to top]

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

[back to top]

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT03805932)
Timeframe: Date treatment consent signed to date off study, approximately 11 months and 13 days for the first group, and 4 months and 3 days for the second group.

InterventionParticipants (Count of Participants)
Moxetumomab - Dose Escalation 30 mcg/kg3
Moxetumomab - Dose Expansion 40 mcg/kg15

[back to top]

Number of Participants With a Dose-limiting Toxicity (DLT)

Dose limiting toxicity (DLT) is defined as all treatment related Grade 3-5 adverse events (AEs) occurring from the initiation of moxetumomab pasudotox-tdfk therapy to within 30 days after the last dose of moxetumomab pasudotox-tdfk treatment. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to adverse event. (NCT03805932)
Timeframe: From the initiation of moxetumomab pasudotox-tdfk therapy to within 30 days after the last dose

InterventionParticipants (Count of Participants)
Moxetumomab - Dose Escalation 30 mcg/kg0
Moxetumomab - Dose Expansion 40 mcg/kg0

[back to top]

Number of Participants Whose Cancer Shrinks or Disappears After Treatment

Number of participants whose cancer shrinks or disappears after treatment defined as minimal residual disease. MRD is no hairy cell leukemia (HCL) in the blood and bone marrow aspirate flow determined by immunohistochemistry (IHC) and flow cytometry of blood and bone marrow aspirate. (NCT03805932)
Timeframe: 28-42 days after day 1 of the last treatment.

InterventionParticipants (Count of Participants)
Moxetumomab - Dose Escalation 30 mcg/kg2
Moxetumomab - Dose Expansion 40 mcg/kg11

[back to top]

Number of Participants Who Are Minimal Residual Disease (MRD)-Free

MRD-free is defined as participants with no hairy cell leukemia (HCL) in the blood and bone marrow aspirate flow determined by immunohistochemistry (IHC) and flow cytometry of blood and bone marrow aspirate. (NCT03805932)
Timeframe: 28-42 days after day 1 of the last treatment.

InterventionParticipants (Count of Participants)
Moxetumomab - Dose Escalation 30 mcg/kg2
Moxetumomab - Dose Expansion 40 mcg/kg11

[back to top] [back to top] [back to top]

Adverse Events

Number of adverse events reported (NCT04248712)
Timeframe: 12 weeks

Interventionadverse events (Number)
Treatment Group0

[back to top]

Change in Maximum Eosinophil Count

Calculated by maximum eosinophils per esophagogastroduodenoscopy (EGD) high-power field (eos/hpf) after therapy with antihistamines. As measured by the percentage of change in maximum eosinophil count from baseline to 12 weeks. (NCT04248712)
Timeframe: 12 weeks

Interventionpercentage change (Number)
Treatment Group0

[back to top] [back to top]

Time to Symptom Resolution

Days to resolution of symptoms of infection. (NCT04545008)
Timeframe: 0 to 30 days

Interventiondays (Mean)
Low Dose N-Acetyl Cysteine Alone6

[back to top]

Rate of Hospitalization

Number of participants hospitalized (NCT04545008)
Timeframe: 0 to 30 days

Interventionparticipants (Number)
Low Dose N-Acetyl Cysteine Alone0

[back to top]